

**METALLOPROTEINASE-DISINTEGRIN FAMILY MEMBERS:  
SVPH DNAS AND POLYPEPTIDES**

**CROSS REFERENCE TO RELATED APPLICATIONS**

This application hereby claims the benefit of United States provisional applications S.N. 60/116,670; S.N. 60/138,682; and S.N. 60/155,798; filed January 21, 1999; June 14, 1999; and September 27, 1999, respectively. The entire disclosures of these applications are relied upon and incorporated by reference herein.

**BACKGROUND OF THE INVENTION**

**Field of the Invention**

The invention is directed to purified and isolated, novel SVPH polypeptides (SVPH-1, SVPH-1a, SVPH-1b, SVPH-1c; SVPH-3; and SVPH-4, SVPH-4a, and SVPH-4b) and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses thereof.

**Description of Related Art**

Metalloproteinases are a group of proteinases characterized by the presence of a metal prosthetic group. Despite this basic similarity, the group, which includes proteinases from snake venom, numerous microbial proteinases, and vertebrate and bacterial collagenases, would seem to present proteinases of seemingly widely varying activities. For example, snake venom proteases are metalloproteinases that affect cell-matrix interactions. Snake venom also includes "disintegrins," a class of low molecular weight, Arg-Gly-Asp (RGD)-containing, cysteine-rich peptides which bind to integrins (a family of molecules involved in cell-to-cell adhesion, cell-to-matrix adhesion, and inflammatory responses) expressed on cells.

disintegrin-like, cysteine rich, and epidermal growth factor domains. See, Black et al., "ADAMs: focus on the protease domain," *Curr. Opin. Cell Biol.* 10: 61-67 (1998).

See also, Black et al., "ADAMs: focus on the protease domain," *Curr. Opin. Cell Biol.* 10: 61-67 (1998).

401 (1996), all of which are herein incorporated by reference. The metalloproteinase-disintegrins or ADAMs have a unique domain structure composed of a signal sequence, pro-domain with a Cys switch, catalytic domain with a zinc binding motif, disintegrin domain, cysteine-rich domain, a transmembrane domain, and a cytoplasmic domain (Black et al., "ADAMs: focus on the protease domain," *Curr. Opin. Cell Biol.* 10:654-659 (1998) ; Blobel, C. P., *Cell*, 90:589-592 (1997)). Thus, ADAMs are type 1 transmembrane proteins expressed on the cell surface. ADAMs have been isolated from mammalian species, *Caenorhabditis*, *Xenopus*, and *Drosophila*. Approximately half of the ADAMs do not contain the zinc-binding motif **HEXXHXXGXXHD** (SEQ ID NO:31), which is thought to be required for enzymatic activity. However, all ADAMs contain the disintegrin domain, which is approximately 80 amino acids in length with 15 highly conserved Cys residues. In some members this region has been found to bind integrins (Almeida, E.A. et al., *Cell* 81:1095-1104 (1995); Zhang, X. P. et al., *J. Biol. Chem.* 273:7345-7350 (1998); Nath, D. et al., *J. Cell Sci.* 112:579-587 (1999)), although the role of this domain for the majority of the family members is unknown.

Over two dozen ADAMs have been identified but only a few have had their biological roles elucidated. Tumor necrosis factor- $\alpha$  converting enzyme (TACE/ADAM17) was isolated as the proteinase required for the shedding of TNF- $\alpha$  from the plasma membrane. See, Blobel, C.P., *Cell*, 90:589-592 (1997); Moss, M. et al., *Nature* 385:733-736 (1997); Black, R.A. et al., *Nature* 385:729-733 (1997). More recently TACE/ADAM17 has been found to be required for the ectodomain shedding of other cell surface proteins including I-selectin, TGF- $\alpha$ , p80 TNFR, p60TNFR, I-selectin, type II IL-1R, and  $\beta$ -amyloid precursor protein (Peschon, J. J. et al., *Science* 282:1281-1284 (1998)). Fertilin- $\alpha$ /ADAM1 and fertilin- $\beta$ /ADAM2 are required for sperm-egg fusion (Myles, D. G. et al., *Proc. Nat'l. Acad. Sci., USA* 91:4195-4198 (1994)) while meltrin  $\alpha$ /ADAM12 has a role in muscle cell fusion (Yagami-Hirano, Y. et al., *Nature*, 377:652-656 (1995)). In addition, MDC-1/ADAM11 is

280 (1997), Roeder, J. et al., *Science* 273: 1227-1231 (1996))

Some ADAMs are ubiquitously expressed such as ADAM9, ADAM10, ADAM15, and ADAM17 and may have pleiotropic effects, as has been found for ADAM15 and ADAM17. Many of the other ADAMs, however, show tissue-specific expression: ADAM12 and ADAM19 in muscle (Yagami-Hiromasa, T. et al., *Nature* 377:652-656 (1995)), ADAM22 in brain, and ADAM23 in brain and heart (Sagane, K. et al., *J. Biochem.* 334:93-98 (1998)). The largest group of ADAMs (Bjarnason, J. B. et al., *Methods Enzymol.* 248: 345-368 (1995); Jia, L. G. et al., *Toxicon* 34:1269-1276 (1996); Stocker, W. et al., *Protein Sci.* 4:823-840 (1995); Black, R. A. et al., *Curr. Opin. Cell Biol.* 10:654-659 (1998); Blobel, C. P., *Cell* 90:589-592 (1997); Almeida, E. A. et al., *Cell* 81:1095-1104 (1995); Zhang, X. P. et al., *J. Biol. Chem.* 273:7345-7350 (1998); Wolfsberg, T. G. et al., *Dev. Biol.* 180:389-401 (1996); Zhu, G. Z. et al., *Gene* 234:227-237 (1999); Blobel, C. P. et al., *Nature* 356:248-252 (1992); Walter, M. A. et al., *Nat. Genet.* 7:22-28 (1994); Gribskov, M. et al., *Nucleic Acids Res.* 14:6745-6763 (1986); Bode, W. et al., *FEBS Lett.* 331:134-140 (1993); and Cerretti, D. P. et al., *Cytokine* 11:541-551 (1999)) is predominately expressed in testis and is thought to be involved in spermatogenesis and fertilization (Wolfsberg, T. G. et al., *Dev. Biol.* 180:389-401 (1996); Hooft van Huijsduijnen, R., *Gene* 206:273-282 (1998); Zhu, G. Z. et al., *Gene* 234:227-237 (1999)). Indeed, the first mammalian ADAMs discovered, ADAM1 and ADAM2, were found to be required for sperm-egg fusion (Zhu, G. Z. et al., *Gene* 234:227-237 (1999)).

The ADAMs family of metalloproteinase-disintegrins also share homology with the snake venom protease family (SVPH). In some snake venom protease members, the disintegrin domain prevents platelet aggregation and thus acts as an anti-coagulant.

Given the significant function of metalloproteinases in membrane and cell-cell fusion, cellular adhesion, shedding of membrane proteins, and anti-coagulation, there is a need in the art for additional metalloproteinases of the ADAMs family and/or the

In another aspect, the identification of the primary structure, or sequence, of an unknown protein is the culmination of an arduous process of experimentation. As

order to identify an unknown protein, the investigator can rely upon a comparison of the unknown protein to known peptides using a variety of techniques known to those skilled in the art. For instance, proteins are routinely analyzed using techniques such as electrophoresis, sedimentation, chromatography, sequencing and mass spectrometry.

In particular, comparison of an unknown protein to polypeptides of known molecular weight allows a determination of the apparent molecular weight of the unknown protein (Brock, T. D. et al., *Biology of Microorganisms* 76-77 (1991)). Protein molecular weight standards are commercially available to assist in the estimation of molecular weights of unknown protein (New England Biolabs Inc. Catalog:130-131 (1995); J. L. Hartley, U.S. Patent No. 5,449,758). However, the molecular weight standards may not correspond closely enough in size to the unknown protein to allow an accurate estimation of apparent molecular weight. The difficulty in estimation of molecular weight is compounded in the case of proteins that are subjected to fragmentation by chemical or enzymatic means, modified by post-translational modification or processing, and/or associated with other proteins in non-covalent complexes.

In addition, the unique nature of the composition of a protein with regard to its specific amino acid constituents results in unique positioning of cleavage sites within the protein. Specific fragmentation of a protein by chemical or enzymatic cleavage results in a unique "peptide fingerprint" (Cleveland, D. W. et al., *J. Biol. Chem.* 252:1102-1106 (1977); Brown, M. et al., *J. Gen. Virol.* 50:309-316 (1980)). Consequently, cleavage at specific sites results in reproducible fragmentation of a given protein into peptides of precise molecular weights. Furthermore, these peptides possess unique charge characteristics that determine the isoelectric pH of the peptide. These unique characteristics can be exploited using a variety of electrophoretic and other techniques (Brock, T. D. et al., *Biology of Microorganisms* 76-77 (Prentice Hall, 6th ed. 1991)).

(1987); Eckerskorn, C. et al., *Electrophoresis* 9:830-838 (1988), particularly

the production of fragments from proteins with a "blocked" N-terminus. In addition, fragmented proteins can be used for immunization, for affinity selection (R. A. Brown, U.S. Patent No. 5,151,412), for determination of modification sites (e.g. phosphorylation), for generation of active biological compounds (Brock, T. D. et al., *Biology of Microorganisms* 300-301 (Prentice Hall, 6th ed. 1991)), and for differentiation of homologous proteins (Brown, M. et al., *J. Gen. Virol.* 50:309-316 (1980)).

In addition, when a peptide fingerprint of an unknown protein is obtained, it can be compared to a database of known proteins to assist in the identification of the unknown protein using mass spectrometry (Henzel, W. J. et al., *Proc. Natl. Acad. Sci. USA* 90:5011-5015 (1993); Fenyo, D. et al., *Electrophoresis* 19:998-1005 (1998)). A variety of computer software programs to facilitate these comparisons are accessible via the Internet, such as Protein Prospector (Internet site: [prospector.uscf.edu](http://prospector.uscf.edu)), Multident (Internet site: [www.expasy.ch/sprot/multiident.html](http://www.expasy.ch/sprot/multiident.html)), PeptideSearch (Internet site: [www.mann.embl-heidelberg.de/deSearch/FR\\_PeptideSearchForm.html](http://www.mann.embl-heidelberg.de/deSearch/FR_PeptideSearchForm.html)), and ProFound (Internet site: [www.chait-sgi.rockefeller.edu/cgi-bin/prot-id-frag.html](http://www.chait-sgi.rockefeller.edu/cgi-bin/prot-id-frag.html)). These programs allow the user to specify the cleavage agent and the molecular weights of the fragmented peptides within a designated tolerance. The programs compare these molecular weights to protein molecular weight information stored in databases to assist in determining the identity of the unknown protein. Accurate information concerning the number of fragmented peptides and the precise molecular weight of those peptides is required for accurate identification. Therefore, increasing the accuracy in determining the number of fragmented peptides and their molecular weight should result in enhanced likelihood of success in the identification of unknown proteins.

In addition, peptide digests of unknown proteins can be sequenced using tandem mass spectrometry (MS/MS) and the resulting sequence searched against

known protein sequences (1999). Searching programs that can be used in this process exist on the Internet, such as Entefish 97 (Internet site: [www.klbc.com/70/Entefish97.htm](http://www.klbc.com/70/Entefish97.htm)).

and the Protein Prospector, Peptide Search and ProFound programs described above. Therefore, adding the sequence of a gene and its predicted protein sequence and peptide fragments to a sequence database can aid in the identification of unknown proteins using tandem mass spectrometry.

Thus, there also exists a need in the art for polypeptides suitable for use in peptide fragmentation studies, for use in molecular weight measurements, and for use in protein sequencing using tandem mass spectrometry.

### **SUMMARY OF THE INVENTION**

The invention aids in fulfilling these various needs in the art by providing isolated, novel SVPH nucleic acids and polypeptides encoded by these nucleic acids. Particular embodiments of the invention are directed to an isolated SVPH nucleic acid molecule comprising the DNA sequence of SEQ ID NOs:1-3 and isolated SVPH nucleic acid molecules encoding the amino acid sequence of SEQ ID NOs:4-6, as well as nucleic acid molecules complementary to these sequences. Further studies have revealed the full-length nucleotide sequences of three alternatively spliced SVPH-1 clones (SEQ ID NOs:7-9) and two alternatively spliced SVPH 4 clones (SEQ ID NOs:10-11). Thus, further embodiments of the invention are directed to an isolated SVPH nucleic acid molecule comprising the DNA sequence of SEQ ID NOs:7-11 and isolated SVPH nucleic acid molecules encoding the amino acid sequence of SEQ ID NOs:12-16, as well as nucleic acid molecules complementary to these sequences. Both single-stranded and double-stranded RNA and DNA nucleic acid molecules are encompassed by the invention, as well as nucleic acid molecules that hybridize to a denatured, double-stranded DNA comprising all or a portion of SEQ ID NOs:1-3 and 7-11. Also encompassed are isolated nucleic acid molecules that are derived by *in vitro* mutagenesis of nucleic acid molecules comprising sequences of SEQ ID NOs:1-3 and 7-11, that are degenerate from nucleic acid molecules comprising sequences of SEQ ID NOs:1-3 and 7-11, and that hybridize to a denatured, double-stranded DNA comprising all or a portion of SEQ ID NOs:1-3 and 7-11.

with these vectors.

In addition, the invention encompasses methods of using the nucleic acids noted above to identify nucleic acids encoding proteins having metalloproteinase-disintegrin activities; to identify human chromosome number 1 or 4; to map genes on human chromosome number 1 or 4; to identify genes associated with certain diseases, syndromes, or other human conditions associated with human chromosome number 1 or 4; and to study proteinases and their activities on cell/cell interactions as well as proteinase activity on the immune system.

The invention also encompasses the use of sense or antisense oligonucleotides from the nucleic acid of SEQ ID NOs:1-3 and 7-11 to inhibit the expression of the polynucleotides encoded by the SVPH-1, SVPH-3, or SVPH-4 genes.

The invention also encompasses isolated polypeptides and fragments thereof encoded by these nucleic acid molecules including soluble polypeptide portions of SEQ ID Nos:4-6 and 12-16. The invention further encompasses methods for the production of these polypeptides, including culturing a host cell under conditions promoting expression and recovering the polypeptide from the culture medium. Especially, the expression of these polypeptides in bacteria, yeast, plant, insect, and animal cells is encompassed by the invention.

In general, the polypeptides of the invention can be used to study the cell/cell and cell/matrix interactions involved in cellular processes (including cell fusion as in sperm/egg interactions, cell recognition and binding) as well as those involved in the immune system. In addition, these polypeptides can be used to identify other proteins associated with SVPH family members, ADAMs family members, and other metalloproteinases.

In addition, the invention includes assays utilizing these polypeptides to screen for potential inhibitors of activity associated with polypeptide counter-structure molecules, and methods of using these polypeptides as therapeutic agents for the treatment of diseases mediated by SVPH polypeptide counter-structure molecules.

The invention further provides a method for using these polypeptides as antibodies or antibody fragments that allow the identification of these polypeptide counter-

protein or a fragmented protein, as well as a method for the visualization of the molecular weight markers of the invention thereof using electrophoresis. The invention further encompasses methods for using the polypeptides of the invention as markers for determining the isoelectric point of an unknown protein, as well as controls for establishing the extent of fragmentation of a protein. Further encompassed by this invention are kits to aid in these determinations.

Isolated polyclonal or monoclonal antibodies that bind to these polypeptides are also encompassed by the invention, in addition the use of these antibodies to aid in purifying the SVPH polypeptide.

Further encompassed by this invention is the use of the SVPH nucleic acid sequences, predicted amino acid sequences of the polypeptide or fragments thereof, or a combination of the predicted amino acid sequences of the polypeptide and fragments thereof for use in searching an electronic database to aid in the identification of sample nucleic acids and/or proteins.

#### **BRIEF DESCRIPTION OF THE FIGURES**

Figure 1 depicts a Northern blot hybridization showing the tissue specificity of SVPH-1 and SVPH-4.

Figure 2 depicts a phylogenetic tree of metalloproteinase-disintegrins. Branches marked with heavy lines indicate ADAM family members with a consensus zinc-binding motif (**HEXXHXXGXXHD**) (SEQ ID NO:31). The arrow indicates the probable zinc-binding motif containing common ancestor. Lineages in which the zinc-binding site was subsequently lost are denoted with an 'X'. Species abbreviations: Mm, *Mus musculus*; Rn, *Rattus norvegicus*; Hs, *Homo sapiens*; Mt, *Macaca fascicularis*; Oc, *Oryctolagus cuniculus*; Cc, *Cavia cobaya*; Cp, *Cavia porcellus*; So, *Saguinus oedipus*; Pp, *Pongo pygmaeus*; Bt, *Bos taurus*.

#### **DETAILED DESCRIPTION OF THE INVENTION**



## Name: SVPH-1

```

1  ATTTTGTGATA CCACAGTGAC CAACACGGTC ACCTAAGGTG TTCAATTCTT
51  TTATAGCAAGT CTCACTTGCA GTATTGCGG CTCAACAAA AATCCTCTTA
101  CACTGTTCAH TTGCGGTGAT GACANGCTC (SEQ ID NO:1)

```

## Name: SVPH-3

```

1  TT'TTTGAGTA AGAATAGGTC ATGTTTTAGT AAAACTTCCA AAAGAACAAA
51  ACAGATTCTT CAACCCAGGA GGACATGTGA GTCACAATAC CCTTTAATCC
101  ACAGGTTGGC TCCTTGGTTT CTGGAAC'TT CTGCCTCCTG TAAACGATGT
151  GCGGGTGGTA CCCTCCCTCA ACCAGTGGAT GCTTCTTCAC GGGTTCAATG
201  AAAAAGTCTC CATGTGGTAG TTGGAAAAAT CCAGTCAGTC CATGGCAGGC
251  ACTGAGGGGT GCCGTCCCAA CTCTGGTGCC CTGCTGTAGA ACCGTGCCAC
301  TGAGATCCCA GAGCGGGGCA GAGGAAGCCA TCATCTTAAC ATGGGAGAGG
351  TTCCCATATC TCTTCTCCAT GATGTAGCTA TTGGAAAGAA ATCCTTCATT
401  GACCGTCAAG TTAAAAACA GGTCTTCTC CTCGTGAGAA ATTCTGTAGT
451  ACACCCAGTC CTCTGAGCC (SEQ ID NO:2)

```

## Name: SVPH-4

```

1  CACGAGGATT TATATCTTCA AAGAAAATAT AATGATGCTC TTGCATGGTC
51  GTTTGGAAAA GTGTGTTCTC TAGAATATGC TGGATCAGTG AGTACTTTAC
101  TAGATACAAA TATCCTTGCC CCTGCTACCT GGTCTGCTCA TGAGCTGGGT
151  CATGCTGTAG GAATGTCACA TGATGAACAA TACTGCCAAT GTAGGGGTAG
201  GCCTAATTGC ATCATGGGCT CAGGACGCAC TGGGT'TAGC AATTGCAGTT
251  ATATCTCTTT TTTTAAACAT ATCTCTTCGG GAGCAACATG TCTAAATAAT
301  ATCCCAGGAC TAGGTTATGT GCTTAAAGAGA TGTGGAAACA AAATTGTGGA
351  GGACAATGAG GAATGTGATT GTGGTTCCAC AGAGGAGTGT CAGAAAGATC
401  GGTGTTGCCA ATCAAATTGT AAGTTGCAAC CAGGTGCCAA CTGTAGCATT
451  GGACTTTGCT GTCATGATTG TCGGTTTCGT CCATCTGGAT ACGTGTGTAG
501  GCAGGAAGGA AATGAATGTG ACCTTGCAAG GTACTGCGAC GGGAATTCAA
551  GTTCTGCCCC AAATGACGTT TATAAGCAGG ATGGAACCCC TTGCAAGTAT
601  GAAGGCCGTT GTTTCAGGAA GGGGTGCAGA TCCAGATATA TGCAGTGCCA
651  AAGCATT'TT GGACTGATG CCATGGAGGC TCTAGTGAG TGCTATGATG
701  CAGTTAACTT AATAGGTGAT CAATTTGGTA ACTGTGAGAT TACAGGAATT
751  CGAAATTTTA AAAAGTGTGA AAGTGCAAAAT TCAATATGTG GCAGGCTACA
801  GTGTATAAAT GTTGAACCA TCCCTGATTT GCCAGAGCAT ACCACTATAA
851  TTTCTACTCA TTTACAGGCA GAAAACTCA TGTGCTGGGG CACAGGCTAT
901  CATCTATCCA TGAACCCAT GSGAATACCT GACCTAGGTA TGATAAATGA
951  TGGCACCTCC TGTGGAGAAG GCCGGSTATG TTTTAAAAAA AATTGCGTCA
1001  ATAGCTCAGT CCTGCAGTTT GACTGTTTGC CTGAGAAATG CAATACCCGG
1051  GGTGTTTGCA ACAACAGAAA AAAGTGCCAC TGCATGTATG GGTGGGCAAC
1101  TCCATTCTGT GAGGAAGTGG GGTATGGAGG AAGCATTGAC AGTGGGCTC

```

## Name: SVPH-5 (SVPH-1 and SVPH-3)

```

1301  ACTCAAGAAA TCAAACTAA AATGTGACA TAAAGAACTT AATCAAACTA
1351  TTGAAAGTAA AAGACAAA CCAAGAGTG TAAAGAAACA AAAAATTA

```

## Name: SVPH-1a

```

1   ATGAAGATGT TACTCCTGCT GCATTGCCTT GGGGTGTTTG TGTCTCTTTT
51  TGGACACATG CAGGATGAGG ACCCCCAATA TCACAGCCCT CCGTATGTGG
101 TGATTCTCTG GAGGATAACT GGCACACCA GAGGCATGAC AGCTCCAGGT
151 TGGCTCTCTT ATATCCTGCC CTTTGGAGGG CAGAAACACA TTATCCACAT
201 AAAGGTCAAG AAGCTTTTGT TTTCCAAACA CCTCCCTGTG TTCACCTACA
251 CAGACCAGGG TGCTATCCTT GAGGACCAGC CATTGTCCCA GAATAACTGC
301 TACTATCATG GTTATGTGGA AGGGGACCCA GAATCCCTGG TTTCCCTCAG
351 TACCTGTTTT GGGGGTTTTT AAGGAATATT ACAGATAAAT GACTTTGCTT
401 ATGAAATCAA GCCCCTAGCA TTTTCTACCA CGTTTGAACA TCTGCTATAC
451 AAGATGGACA GTGAGGAGAA ACAATTTTCA ACCATGAGAT CCGGATTTAT
501 GCAAAATGAA ATAACATGCC GAATGGAATT TGAAGAAATT GATAATTCCA
551 CTCAGAAGCA AAGTTCTTAT GTGGGCTGGT GGTATCCATT TATGATTGTT
601 GAAATTGTAG TCGTCATTGA TAATTATCTG TACATTCTGT ATGAAAGGAA
651 CGACTCAAAG TTGCTGGAGG ATCTATATGT TATTGTAAAT ATAGTGGATT
701 CCATTTTGGG TGTCATTGCT GTTAAGGTGT TATTATTTGG TTTGGAGATC
751 TGGACCAATA AAAACCTCAT TGTAGTAGAT GATGTAAGGA AATCTGTGCA
801 CCTGTATTGC AAGTGGAAAT CGGAGAACAT TACGCCCCGG ATGCAACATG
851 ACACCTCACA TCTTTTCACA ACTCTAGGAT TAAGAGGGTT AAGTGGCATA
901 GGAGCTTTTA GAGGAATGTG TACACCACAC CGTAGTTGTG CAATTGTTAC
951 TTTTCATGAC AAAACTTTGG GCACTTTTTC AATTGCAGTG GCTCATCATC
1001 TAGGTCATAA TTTGGGCATG AACCATGATG AGGATACATG TCGTTGTTCa
1051 CAACCTAGAT GCATAATGCA TGAAGGCAAC CCACCAATAA CTAAATTTAG
1101 CAATTGTAGT TATGGTGATT TTTGGGAATA TACTGTAGAG AGGACAAAGT
1151 GTTTGCTTGA AACAGTACAC ACAAAAGACA TCTTTAATGT GAAGCGCTGT
1201 GGGAAATGGT TTGTTGAAGA AGGAGAAGAG TGTGACTGTG GACCTTTAAA
1251 GCATTGTGCA AAAGATCCCT GCTGTCTGTG AAATTGCACT CTGACTGATG
1301 GTTCTACTTG TGCTTTTGGG CTTTGTGCA AAGACTGCAA GTTCTACCA
1351 TCAGGSAAG TGTGTAGAAA GGAGGTCAAT GAATGTGATC TTCCAGAGTG
1401 GTGCAATGGT ACTTCCCATA AGTCCCAGA TGACTTTTAT GTGGAAGATG
1451 GAATTCCCTG TAAGGAGAGG GCTACTGCT ATGAAAAGAG CTGTCTATGAC
1501 CGCAATGAAC AGTGTAGGAG GATTTTGTGT GCAGGCGCAA ATACTGCAAG
1551 TGAGACTTGC TACAAAGAAT TGAACACCTT AGGTGACCGT GTTGGTCACT
1601 GTGGTATCAA AAATGCTACA TATATAAAGT GTAATATCTC AGATGTCCAG
1651 TGTGGAAGAA TTCAGTGTGA GAATGTGACA GAAATTTCCA ATATGAGTGA
1701 TCATACTACT GTGCATTGGG CTCGCTTCAA TGACATAATG TGCTGGAGTA
1751 CTGATTACCA TTTGGGGATG AAGGGACCTG ATATTGGTGA AGTGAAAGAT
1801 GGAACAGAGT GTGGGATAGA TCATATATGC ATCCACAGGC ACTGTGTCCA
1851 TATAACCATG TTGAATAGTA ATTGCTCAGC TGCATTTTGT AACAGAAGG
1901 GATCTGCAA CAATAAACAT CACTGCCATG GCAATTATCT GTGGGACCT
1951 CCAAACCTGC TGATAAAAAGG CTATGGAGGT AGTGTTCACA GTGGCCCAAC
2001 CCTAAGAGA AAGAAGAAAA AGAAATCTG TTATCTGTGT ATATTGTTC
2051 TTATTGTTTT GTTTATTTTA TTATGTTGTC TTTATCGACT TTGTAAAAAA
2101 AGTAAACCAA TAAAAAGCA GCAAGATGTT CAAACTCCAT CTGCAAAAGA
2151 AGAGGAAAAA ATTCAGCGTC GACCTCATGA GTTACCTCCC CAGAGTCAAC
2201 CTTGGGTGAT GCCTTCCCAG AGTCAACCTT CTTGACAGC CTCCCAGAGG
2251 CAACCTCACT TGATGCTTTC CAGAGTCAA CTTCTTTTGA GGGCTCTTA
2301 G (SEQ ID NO: 1)

```

FIG. 1

1. Amino acid sequence of SVPH-1a (1-230) (SEQ ID NO: 1)

```

101  TGAATTCCTGT GAGGATAAAGT GGCACCACCA GAGGCATGAC ACCTCCAGG
151  TGGCTTCCTT ATATCCTGCC CTTTGGAGGC CAGAAACACA TTATCCACAT
201  AAAGGTCAGG AAGCTTTTGT TTTCCAAACA CTTCCCTGTG TTCACTTACA
251  CAGACCAAGG TGTATTCCTT GAGGACCAAG CATTGTGTCA GAATAACTGC
301  TACTATCATG GTTATGTGGA AGGGGACCCA GAATCCCTGG TTTCCCTCAG
351  TACCTGTTTT GGGGTTTTTC AAGGAATATT ACAGATAAAT GACTTTGCTT
401  ATGAAATCAA GCCCCTAGCA TTTTCTACCA CGTTTGAACA TCTGTTATAC
451  AAGATGGACA GTGAGGAGAA ACAATTTTCA ACCATGAGAT CCGGATTTAT
501  GCAAAATGAA ATAACATGCC GAATGGAATT TGAAGAAATT GATAATTCCA
551  CTCAGAAGCA AAGTTCTTAT GTGGGCTGCT GGATCCATTT TAGGATTGTT
601  GAAATTGTAG TCGTCATTGA TAATTATCTG TACATTGCTT ATGAAAGGAA
651  CGACTCAAAG TTGCTGGAGG ATCTATATGT TATTGTTAAT ATAGTGGATT
701  CCATTTTGGG TGTCATTGGT GTTAAGGTGT TATTATTTGG TTTGGAGATC
751  TGGACCAATA AAAACCTCAT TGTAGTAGAT GATGTAAGGA AATCTGTGCA
801  CCTGTATTGC AAGTGGAAGT CGGAGAACAT TACGCCCCGG ATGCAACATG
851  ACACCTCACA TCTTTTCACA ACTCTAGGAT TAAGAGGGTT AAGTGGCATA
901  GGAGCTTTTA GAGGAATCTG TACACCACAC CGTAGTTGTC CAATTGTTAC
951  TTTTCATGAAC AAAACTTTGG GCCTTTTTC AATTGCACTG GCTCATCATC
1001 TAGGTCATAA TTTGGGCATG AACCATGATG AGGATACATG TCGTTGTTCA
1051 CAACCTAGAT GCATAATGCA TGAAGGCAAC CCACCAATAA CTAAATTTAG
1101 CAATTGTAGT TATGGTGATT TTTGGGAATA TACTGTAGAG AGGACAAAGT
1151 GTTTGCTTGA AACAGTACAC ACAAAGGACA TCTTTAATGT GAAGCGCTGT
1201 GGGAAATGGT TTGTTGAAGA AGGAGAAGAG TGTGACTGTG GACCTTTAAA
1251 GCATTGTGCA AAAGATCCCT GCTGTCTGTC AAATTGCACT CTGACTGATG
1301 GTTCTACTTG TGCTTTTGGG CTTTGTGCA AAGACTGCAA GTTCTTACCA
1351 TCAGGGAAAG TGTGTAGAAA GGAGGTCAAT GAATGTGATC TTCCAGAGTG
1401 GTGCAATGGT ACTTCCCATA AGTGCCGAGA TGACTTTTAT GTGGAAGATG
1451 GAATTCCTTG TAAGGAGAGG GGCTACTGCT ATGAAAAGAG CTGTCTATGAC
1501 CGCAATGAAC AGTGTAGGAG GATTTTGGT GCAGGCGCAA ATACTGCAAG
1551 TGAGACTTGC TACAAAGAAT TGAACACCTT AGGTGACCGT GTTGGTCACT
1601 GTGGTATCAA AAATGCTACA TATATAAAGT GTAATATCTC AGATGTCCAG
1651 TGTGGAAGAA TTCAGTGTGA GAATGTGACA GAAATTCCCA ATATGAGTGA
1701 TCATACTACT GTGCATTGGG CTCGCTTCAA TGACATAATG TGCTGGAGTA
1751 CTGATTACCA TTTGGGGATG AAGGGACCTG ATATTGGTGA AGTGAAAGAT
1801 GGAACAGAGT GTGGGATAGA TCATATATGC ATCCACAGGC ACTGTGTCCA
1851 TATAACCATC TTGAATAGTA ATTGCTCACC TGCATTTTGT AACAAGAGGG
1901 GCATCTGCAA CAATAAACAT CACTGCCATT GCAATTATCT GTGGGACCTT
1951 CCCAACTGCC TGATAAAAGG CTATGGAAGT AGTGTGACA GTGGTCCAGC
2001 CCCTAAGAGA AAGAAGAAAA AGAAGTTCTG TTATCTGTGT ATATTGTTGC
2051 TTATGTTTTT GTTTATTTTA TTATGTTGTC TTATCTGACT TTGTAAAAAA
2101 AGTAAACCAA TAAAAAAGCA GCAAGATGTT CAAACTCCAT CTGCAAAAAG
2151 AGAGGAAAAA ATTCAGCGTC GACCTCATGA GTTACCTCCC CAGAGTCAAC
2201 CTTGGGTGAT GCTTCCCAG AGTCAACCTC CTGTGACGCC TTCCAGAGT
2251 CATCCTCAGG TGATGCTTTC CCAGAGTCAA CCTCCTCAAA ATTATTCTT
2301 GTTCAGCTTC TCAATCAGTG ACTGTGTGCT AAATTTTAGG CTACTGTATC
2351 TTCAGGCCAC CTGA (SEQ ID NO:8)

```

```

101  TGAATTCCTGT GAGGATAAAGT GGCACCACCA GAGGCATGAC ACCTCCAGG
151  TGGCTTCCTT ATATCCTGCC CTTTGGAGGC CAGAAACACA TTATCCACAT
201  AAAGGTCAGG AAGCTTTTGT TTTCCAAACA CTTCCCTGTG TTCACTTACA

```

```

251 CAGACCAGGG TGCTATCCTT GAGGACCAGC CATTGTGTTCA GAATAACTGC
301 TACTATCATG GTTATGTGGA AGGGGACCCA GAATCCCTGG TTCCCTCAG
351 TACCTGTTTT GGGGGTTTTT AAGGAATATT ACAGATAAAT GACTTTGTIT
401 ATGAAATCAA GGGGCTAGCA TTTTCTAGCA CGTTTGAACT TCTGTATAC
451 AGATGGAC GTGAGGAGAA ACAATTTTCA ACCATGAGAT CCGATTIAT
501 GCAAAATGAA ATAACATGCC GAATGGAATT TGAAGAAATT GATAAITCCA
551 CTCAGAAGCA AAGTTCTTAT GTGGGCTGGT GGATCCATTT TAGGATTTGT
601 GAAATTGTAG TCGTCATTGA TAATTATCTG TACATTCGTT ATGAAAGSAA
651 CGACTCAAAG TTGCTGGAGG ATCTATATGT TATGTTAAT ATAGTGSATT
701 CCATTTTGGG TGTCATTGCT GTTAAGGTGT TATTATTTGG TTTGGAGATC
751 TGGACCAATA AAAACCTCAT TGTAGTAGAT GATGTAAGGA AATCTGTGCA
801 CCTGTATTGC AAGTGGAAAT CGGAGAACAT TACGCCCCGG ATGCAACATG
851 ACACCTCACA TCTTTTCACA ACTCTAGGAT TAAGAGGGTT AAGTGGCATA
901 GGAGCTTTTA GAGGAATGTG TACACCACAC CGTAGTTGTG CAATTGTTAC
951 TTTTCATGAA AAAACTTTGG GCACTTTTTC AATTGCAGTG GCTCATCATC
1001 TAGGTCATAA TTTGGGCATG AACCATGATG AGGATACATG TCGTTGTTCA
1051 CAACCTAGAT GCATAATGCA TGAAGGCAAC CCACCAATAA CTAAATTTAG
1101 CAATTGTAGT TATGGTGATT TTTGGGAATA TACTGTAGAG AGGACAAAGT
1151 GTTTGCTTGA AACAGTACAC ACAAAAGACA TCTTTAATGT GAACCGCTGT
1201 GGGAAATGCTG TTGTTGAAGA AGGAGAAGAG TGTGACTGTG GACCTTTAAA
1251 GCATTGTGCA AAAGATCCCT GCTGCTGTGC AAATTGCACT CTGACTGATG
1301 GTTCTACTTG TGCTTTTGGG CTTTGTTGCA AAGACTGCAA GTTCCCTACCA
1351 TCAGGGAAAG TGTGTAGAAA GSAGGTCAAT GAATGTGATC TTCCAGAGTG
1401 GTGCAATGGT ACTTCCCATA AGTGCCCGA TGACTTTTAT GTGSAAGATG
1451 GAATTCCCTG TAAGGAGAGG GGCCTACTGCT ATGAAAAGAG CTGTCTAGAC
1501 CGCAATGAAC AGTGTAGGAG GATTTTGGT GCAGGCGCAA ATACTGCAAG
1551 TGAGACTTGC TACAAAGAAT TGAACACCTT AGGTGACCGT GTTGGTCACT
1601 GTGSTATCAA AAATGCTACA TATATAAAGT GTAATATCTC AGATGTCCAG
1651 TGTGGAAGAA TTCAGTGTGA GAATGTGACA GAAATTCCCA ATATGAGTGA
1701 TCATACTACT GTGCATTGGG CTCGCTTCAA TGACATAATG TGCTGGAGTA
1751 CTGATTACCA TTTGGGGATG AAGGGACCTG ATATTGGTGA AGTGAAAGAT
1801 GGAACAGAGT GTGGGATAGA TCATATATGC ATCCACAGGC ACTGTGTCCA
1851 TATAACCATC TTGAATAGTA ATTGCTCACC TGCATTTTGT AACAAGAGGG
1901 GCATCTGCAA CAATAAACAT CACTGCCATT GCAATTATCT GTGGGACCTT
1951 CCCAACTGCC TGATAAAAGG CTATGGAGGT AGTGTGACA GTGGCCCAAC
2001 CCCTAAGAGA AAGAAGAAAA AGAAGTTCTG TTATCTGTGT ATATTGTTGC
2051 TTATTGTTTT GTTTATTTTA TTATGTTGTC TTTATCGACT TTGTAAAAAA
2101 AGTAAACCAA TAAAAAAGCA GCAAGATGTT CAAACTCCAT CTGCAAAAAG
2151 AGAGGAAAAA ATTCAGCGTC GACCTCATGA GTTACCTCCC CAGAGTCAAC
2201 CTTGGGTGAT GCCTTCCCAG AGTCAACCTC CTGTGACGCC TTCCCAGAGT
2251 CATCCTCGGG TGATGECTTC TCAGAGTCAA CCTCCTGTGA TGCCTTCCCA
2301 GAGTCATCCT CAGTTGAGGC CTTCCTCAGG TCAACCTCCT GTGATGCTTT
2351 CCCAGAGTCA TCTTCAGTTG AGGCTTCCC AGAGTCAACC TCCTGTGACA
2401 CCTCCCTAGA GSCAACTCA GTTGATGCC TCCCAGAGTC AACCTCCTGT
2451 GACGCCCTCC TAG (SEQ ID NO:9)

```

Name: SVPH-4a

```

1000 TTTAAAAATTT AAGAAATTA TTTTATTTT TTCTTCAAA TAAATTTTAT
1001 TGTAAAGATA TTTTAAATTT TTTTCTTCA CAAATATGT CAAATTTTAT

```

301 GAGGATCATC CTTACATACC AAAGGACTGC AACTACATGG GCTCCGTGAA  
 351 AGAGTCTCTG GACTCTAAAG CTACTATAAG CACATGCATG GGGGCTCTCC  
 401 GAGGTGTATT TAACATTGAT GCCAAACATT ACUAAATTGA GCGCTTCAAG  
 451 GCTCTCCCA GTTTTGAACA TGTGTTCTAT CTCTGAAGA AAGAGCAGTT  
 501 TGGGAATCAG GTTTGTGGCT TAAGTGATGA TGAATAGAA TGGCAGATGG  
 551 CCGCTTATGA GAATAAGGCG AGGCTAAGGG ACTTCTCTGG ATCCTATAAA  
 601 CACCCAAAGT ACTTGGAATT GATCTACTC TTTGATCAAA GTAGGTATAG  
 651 GTTTGTGAAC AACAATCTTT CTCAAGTCAT ACATGATGCC ATTCTTTTGA  
 701 CTGGGATTAT GGACACCTAC TTTCAGATG TCTGATGAG GATACACTTA  
 751 AAGGCTCTTG AAGTATGSAC AGATTTTAAC AAAATACGGG TTGGATATCC  
 801 AGAGTTAGCT GAAGTTTTAG GCAGATTTGT AATATATAAA AAAAGTGTAT  
 851 TAAATGCTCG CCTGTCATCA GATTGGGCAC ATTTATATCT TCAAAGAAAA  
 901 TATAATGATG CTCTTGATG GTCGTTTGA AAAAGTGTGT CTCTAGAATA  
 951 TGCTGGATCA GTGAGTACTT TACTAGATAC AAATATCCCT GCGGCTGCTA  
 1001 CCTGGTCTGC TCATGAGCTG GGTCAATGCT TAGGAATGTC ACATGATGAA  
 1051 CAATACTGCC AATGTAGGGG TAGGCCTAAT TGCATCATGG GCTCAGGACG  
 1101 CACTGGGTTT AGCAATTGCA GTTATATCTC TTTTCTTAAA CATATCTCTT  
 1151 CGGAGCAAC ATGTCTAAAT AATATCCAG GACTAGGTTA TGTGCTTAAG  
 1201 AGATGTGGAA ACAAAATTGT GGAGGACAAT GAGGAATGTG ATTGTGTTTC  
 1251 CACAGAGGAG TGTCAAGAAG ATCGGTGTG CCAATCAAAAT TGTAASTTGC  
 1301 AACCAGGTGC CAACTGTAGC ATTGGACTTT GCTGTCATGA TTGTCTTTT  
 1351 CGTCCATCTG GATACGTGTG TAGGCAGGAA GGAAATGAAT GTGACCTTGC  
 1401 AGAGTACTGC GACGGGAATT CAAGTTCTCT CCAAAATGAC GTTTATAAGC  
 1451 AGGATGGAAC CCCTTGCAAG TATGAAGGCC GTTGTTCAG GAAGGGGTGC  
 1501 AGATCCAGAT ATATGCAGTG CCAAGCATT TTTGGACCTG ATGCCATGGA  
 1551 GGTCTCTAGT GAGTGCTATG ATGCAGTTAA CTTAATAGGT GATCAATTTG  
 1601 GTAACGTGA GATTACAGGA ATTCGAAATT TAAAAAGTG TGAAGTGCA  
 1651 AATTCAATAT GTGGCAGGCT ACAGTGTATA AATGTTGAAA CCATCCCTGA  
 1701 TTTGCCAGAG CATACGACTA TAATTTCTAC TCATTTACAG GCAGAAAATC  
 1751 TCATGTGCTG GGGCACAGGC TATCATCTAT CCATGAAACC CATGGGAATA  
 1801 CCTGACCTAG GTATGATAAA TGATGGCACC TCCTGTGGAG AAGGGCGGT  
 1851 ATGTTTTTAA AAAAAATTGC TCAATAGCTC AGTCTGTCAG TTTGACTGTT  
 1901 TGCTTGAGAA ATGCAATACC CCGGCTGTTT GCAACAACAG AAAAACTGC  
 1951 CACTGCATGT ATGGGTGGGC ACCTCCATTC TGTGAGGAAG TGGGTATGG  
 2001 AGGAAGCATT GACAGTGGGC CTCCAGGACT GCTCAGAGGG GCGATTCCCT  
 2051 GTCAATTTG GGTGTGTGTC ATCATAATGT TTCGCCTTAT TTTATTAATC  
 2101 CTTTCAGTGG TTTTGTGTGT TTTCCGCAAA GTGATAGGAA ACCACTTAAA  
 2151 ACCCAAACAG GAAAAAATGG CACTATCCAA AGCAAAAACG GAACAGGAAG  
 2201 AATCTAAAAC AAAAACTGTA CAGGAAGAAT CTAAAAACAA AACTGGACAG  
 2251 GAAGAATCTG AAGCAAAAAA TGGACAGGAA GAATCTAAAG CAAAAACTGG  
 2301 ACAGGAAGAA TCTAAAGCAA ACATTGAAAG TAAACGACCC AAAGCAAGA  
 2351 GTGTCAAGAA ACAAAAAAAG TAA (SEQ ID NO:10)

## Name: SYPH-4b

1 AAGAGGTGAG TGCAGATTTT GCTCTCCAA TGGGTTTGG TCTTTCTACG  
 2

301 GAGGATCATC CTTACATACC AAAGGACTGC AACTACATGG GCTCCGTGAA  
 351 AGAGTCTCTG GACTCTAAAG CTACTATAAG CACATGCATG GGGGCTCTCC  
 401 GAGGTGTATT TAACATTGAT GCCAAACATT ACUAAATTGA GCGCTTCAAG  
 451 GCTCTCCCA GTTTTGAACA TGTGTTCTAT CTCTGAAGA AAGAGCAGTT  
 501 TGGGAATCAG GTTTGTGGCT TAAGTGATGA TGAATAGAA TGGCAGATGG  
 551 CCGCTTATGA GAATAAGGCG AGGCTAAGGG ACTTCTCTGG ATCCTATAAA  
 601 CACCCAAAGT ACTTGGAATT GATCTACTC TTTGATCAAA GTAGGTATAG  
 651 GTTTGTGAAC AACAATCTTT CTCAAGTCAT ACATGATGCC ATTCTTTTGA  
 701 CTGGGATTAT GGACACCTAC TTTCAGATG TCTGATGAG GATACACTTA  
 751 AAGGCTCTTG AAGTATGSAC AGATTTTAAC AAAATACGGG TTGGATATCC  
 801 AGAGTTAGCT GAAGTTTTAG GCAGATTTGT AATATATAAA AAAAGTGTAT  
 851 TAAATGCTCG CCTGTCATCA GATTGGGCAC ATTTATATCT TCAAAGAAAA  
 901 TATAATGATG CTCTTGATG GTCGTTTGA AAAAGTGTGT CTCTAGAATA  
 951 TGCTGGATCA GTGAGTACTT TACTAGATAC AAATATCCCT GCGGCTGCTA  
 1001 CCTGGTCTGC TCATGAGCTG GGTCAATGCT TAGGAATGTC ACATGATGAA  
 1051 CAATACTGCC AATGTAGGGG TAGGCCTAAT TGCATCATGG GCTCAGGACG  
 1101 CACTGGGTTT AGCAATTGCA GTTATATCTC TTTTCTTAAA CATATCTCTT  
 1151 CGGAGCAAC ATGTCTAAAT AATATCCAG GACTAGGTTA TGTGCTTAAG  
 1201 AGATGTGGAA ACAAAATTGT GGAGGACAAT GAGGAATGTG ATTGTGTTTC  
 1251 CACAGAGGAG TGTCAAGAAG ATCGGTGTG CCAATCAAAAT TGTAASTTGC  
 1301 AACCAGGTGC CAACTGTAGC ATTGGACTTT GCTGTCATGA TTGTCTTTT  
 1351 CGTCCATCTG GATACGTGTG TAGGCAGGAA GGAAATGAAT GTGACCTTGC  
 1401 AGAGTACTGC GACGGGAATT CAAGTTCTCT CCAAAATGAC GTTTATAAGC  
 1451 AGGATGGAAC CCCTTGCAAG TATGAAGGCC GTTGTTCAG GAAGGGGTGC  
 1501 AGATCCAGAT ATATGCAGTG CCAAGCATT TTTGGACCTG ATGCCATGGA  
 1551 GGTCTCTAGT GAGTGCTATG ATGCAGTTAA CTTAATAGGT GATCAATTTG  
 1601 GTAACGTGA GATTACAGGA ATTCGAAATT TAAAAAGTG TGAAGTGCA  
 1651 AATTCAATAT GTGGCAGGCT ACAGTGTATA AATGTTGAAA CCATCCCTGA  
 1701 TTTGCCAGAG CATACGACTA TAATTTCTAC TCATTTACAG GCAGAAAATC  
 1751 TCATGTGCTG GGGCACAGGC TATCATCTAT CCATGAAACC CATGGGAATA  
 1801 CCTGACCTAG GTATGATAAA TGATGGCACC TCCTGTGGAG AAGGGCGGT  
 1851 ATGTTTTTAA AAAAAATTGC TCAATAGCTC AGTCTGTCAG TTTGACTGTT  
 1901 TGCTTGAGAA ATGCAATACC CCGGCTGTTT GCAACAACAG AAAAACTGC  
 1951 CACTGCATGT ATGGGTGGGC ACCTCCATTC TGTGAGGAAG TGGGTATGG  
 2001 AGGAAGCATT GACAGTGGGC CTCCAGGACT GCTCAGAGGG GCGATTCCCT  
 2051 GTCAATTTG GGTGTGTGTC ATCATAATGT TTCGCCTTAT TTTATTAATC  
 2101 CTTTCAGTGG TTTTGTGTGT TTTCCGCAAA GTGATAGGAA ACCACTTAAA  
 2151 ACCCAAACAG GAAAAAATGG CACTATCCAA AGCAAAAACG GAACAGGAAG  
 2201 AATCTAAAAC AAAAACTGTA CAGGAAGAAT CTAAAAACAA AACTGGACAG  
 2251 GAAGAATCTG AAGCAAAAAA TGGACAGGAA GAATCTAAAG CAAAAACTGG  
 2301 ACAGGAAGAA TCTAAAGCAA ACATTGAAAG TAAACGACCC AAAGCAAGA  
 2351 GTGTCAAGAA ACAAAAAAAG TAA (SEQ ID NO:10)

-14-

```

451  GCGCTCTCCCA GTTTTGAACA TGTCGTCTAT CTCCTGAAGA AAGAGCAGTT
501  TGGGAATCAG GTTTGTGGCT TAAGTGATGA TGAAATAGAA TGGCAGATGG
551  CCGCTTATGA GAATAAGGCG AGGCTAAGGG ACTTTCCTGG ATCCTATAAA
601  CAGCCAAAGT ACTTCGAATT GATCCTACTC TTGATCAAA GTAGGTATAG
651  GTTTGTGAAC AACATCTTT CTCGAAGTCAT ACATGATGCC ATTCCTTTGA
701  CTGGGATTAT GGACACCTAC TTCAAGATG TTGATATAG GATACACTTA
751  AAGGCTCTTG AAGTATGGAC AGATTTTAAAC AAAATACGGG TTGGATATCC
801  AGAGTTAGCT GAAGTTTTAG GCAGATTTGT AATATATAAA AAAAGTGTAT
851  TAAATGCTCC CCTGTCATCA GATTGGGCAC ATTTATATCT TCAAGAAAAA
901  TATAATGATG CTCCTGCATG GTCGTTTGGG AAAGTGTGTT CTCTAGAATA
951  TGCTGGATCA GTGAGTACTT TACTAGATAA AATATCCTT GCGCCTGCTA
1001 CCTGGCCTGG TCATGAGCTG GTCATGCTG TAGGAATGTC ACATGATGAA
1051 CAATACTGCC AATGTAGGGG TAGGCTTAAT TGCATCATGG GCTCAGGACG
1101 CACTGGGTTT AGCAATTGCA GTTATATCTC TTTTTTTAAA CATATCTCTT
1151 CCGGAGCAAC ATGTCTAAAT AATATCCCAG GACTAGGTTA TGTGCTTAAG
1201 AGATGTGGAA ACAAATTGTT GGAGGACAAT GAGGAATGTG ACTGTGGTTC
1251 CACAGAGGAG TGTCAGAAAG ATCGGTGTTG CCAATCAAT TGTAAAGTTG
1301 AACCAAGTGC CAACTGTAGC ATTGGACTTT GCTGTCATGA TTGTGGGTTT
1351 CGTCCATCTG GATACGTGTG TAGGCAGGAA GGAAATGAAT GTGACCTTGE
1401 AGAGTACTGC GACGGGAATT CAAGTTCCTG CCCAAATGAC GTTTATAAGC
1451 AGGATGGAAC CCGTTCGAAG TATGAAGGCC GTTGTTTTCAG GAAGGGGTGC
1501 AGATCCAGAT ATATGCAGTG CCAAGCATT TTTGGACCTG ATGCCATGGA
1551 GGCTCCTAGT GAGTGCATG ATGCAGTTAA CTTAATAGGT GATCAATTTG
1601 GTAACGTGTA GATTACAGGA ATTCGAAATT TTAAAAAGTG TGAAAGTGCA
1651 AATTCAATAT GTGGCAGGCT ACAGTGATAA AATGTTGAAA CCATCCCTGA
1701 TTTGCCAGAG CATAAGACTA TAATTTCTAC TCATTTACAG GCAGAAAAATC
1751 TCATGTGCTG GGGCACAGGC TATCATCTAT CCATGAAACC CATGGGAATA
1801 CCTGACCTAG GTATGATAAA TGATGGCACC TCCTGTGGAG AAGGCCGGGT
1851 ATGTTTTAAA AAAAATTTGG TCAATAGCTC AGTCCTGCAG TTTGACTGTT
1901 TGCTTGAGAA ATGCAATAAC CGGGGTGTTT GCAACAACAG AAAAACTGC
1951 CACTGCATGT ATGGGTGGGC ACCTCCATTC TGTGAGGAAG TGGGGTATGG
2001 AGGAAGCATT GACAGTGGGC CTCAGGACT GCTCAGAGGG GCGATCCCT
2051 CGTCAATTTG GGTGTGTGCC ATCATAATGT TTGCGCTTAT TTTATTAATC
2101 CTTTCAGTGG TTTTGTGTT TTTCGGCAA GTGATAGGAA ACCACTTAAA
2151 ACCCAAACAG GAAAAAATGC CACTATCCAA AGCAAAAAC GAACAGGAAG
2201 AATCTAAAAC AAAAACTGA CAGGAAGAAT CTAAAACAAA AACTGGACAG
2251 GAAGAATCTG AAGCAAAAAC TGGACAGGAA GAATCTAAG CAAACATTGA
2301 AAGTAAACGA CCCAAGCAA AGAGTGTCAG GAAACAAAAA AAGTAA
(SEQ ID NO:11)

```

The amino acid sequences of the polypeptides encoded by the nucleotide sequence of the invention includes:

**Name: SVPH-1 (polypeptide)**

SVPH-1 is a polypeptide having the amino acid sequence: (SEQ ID NO:12)

**Name: SVPII-3 (polypeptide)**

1 EDWVYYPIISH EEKDLFFNI/T VHEGFLNSY IMEERYGNLS HVENMMAGAP  
 51 LCHLSGTVLQ QGTRVGTAAAL SACHSLTGFE QLEHGDEFTL EVEEHELVEG  
 101 GYHPHIVYRR QKVPETKEPT CGL (SEQ ID NO:5)

**Name: SVPII-4 (polypeptide)**

1 HEDLYLQPKY NDALAWSFGK VCSLEYAGSV STLLDTNILA PATWSAHELG  
 51 HAVGMSHDEQ YCQCRGRPNC IMGSGRTGFS NCSYISFFKH ISSGATCLNN  
 101 IPGLGYVLKR CGNKIVEDNE EDCGSTEEC QKDRCCQSNK KLQPGANCSI  
 151 GLCCHDCRFE PSGYVCRQEG NECDLAEYCD GNSSSCPNQV YKQDGTPTCKY  
 201 EGRCFRKQCF SRYMQQSIF GPDAMEAPSE CYDAVNLIGD QFGNCEITGI  
 251 ENFKCESAN SICGRLLQCN VETIFDLPEH TTIISTHLQA ENLMCWGTGY  
 301 HLSMKPMGIP DLGMINDGTS CGEGRVCFKK NCVNSSVLQF DCLPEKCNTR  
 351 GVCNNRKNCH CMYGWAPPFC EEVGYGGSID SGPPGLLRGA IPSSIWVVS  
 401 IMFRLILLIL SVVFVFFRQV IGNHLKPKQE FMPLSKAKTE QEESKTKTVQ  
 451 EESKTKTGQE ESEAKTGQEE SKAKTGQEE FANIESFRPK AKSVKQKK\*  
 (SEQ ID NO:6)

**Name: SVPII-1a (polypeptide)**

1 MKMLLLHCL GVFLSCSGHI QDEHPQYHSP PDVVIPVREIT GTTRGMTTPPG  
 51 WLSYILPFGG QKHIIHIVK KLLFSKHLPV FTYTDQGAIL EDQPFVQNNC  
 101 YYHGYVEGDP ESLVSLSTCF GGFQGIQIN DFAYEIEPLA FSTTFEHLVY  
 151 KMDSEEKQFS TMRSGFMQNE ITCMEFEEI INSTQKQSSY VGWWIHFRIV  
 201 EIVVVIDNYL YIRYERNDSK LLEDLYVIVN IVDSILDVIG VKVLLFGLFI  
 251 WTNKNLIVVD DVRKSVHLYC FWKSENITPR MQHDTSHLFT TLGLRGLSGI  
 301 GAFRGMCTPH RSCAIVTFMN FTLGTFSIAV AHHLGHNLMG NHDEDTCRCS  
 351 QPRCIMHEGN PPITKFSNCS YGDFWEYTV ETKCLLET VH TKDIFNVKRC  
 401 GNGVVEEGEE CDCGPLKHCA KDPCCLSNCT LTDGSTCAFQ LCCCKDCKFLP  
 451 SGKVCERKEVN ECDLPEWCNG TSHKCPDDFY VEDGIPCKER GYCYEKSCHD  
 501 RNEQCCRIFG AGANTASETC YKELNTLGDR VGHCGIKNAT YIKCNISDVQ  
 551 CGRIQCENVT EIFNMSDHTT VHWARFNDIM CWSTDYHLGM KGPDIGEVKD  
 601 GTECGIDHIC IHEHCVHITI LNSNCSPAFC NKGICNNKH HCHCNYLWDP  
 651 PNCLIKGYGG SVDSGPPPKR EFKKKFCYLC ILLLVLFIL LCCLYRLCKK  
 701 SKPIKKQDDV QTPSAKEEEK IQRRPHELPP QSQPWVMPQ SQPPVTSPQ  
 751 QPQLMPSSQ PPVTPS\* (SEQ ID NO:12)

**Name: SVPII-1b (polypeptide)**

1 MEMLLLLHCL GVFLSCSGHI QDEHPQYHSP PDVVIPVREIT GTTRGMTTPPG  
 51 WLSYILPFGG QKHIIHIVK KLLFSKHLPV FTYTDQGAIL EDQPFVQNNC  
 101 YYHGYVEGDP ESLVSLSTCF GGFQGIQIN DFAYEIEPLA FSTTFEHLVY  
 151 KMDSEEKQFS TMRSGFMQNE ITCMEFEEI INSTQKQSSY VGWWIHFRIV  
 201 EIVVVIDNYL YIRYERNDSK LLEDLYVIVN IVDSILDVIG VKVLLFGLFI  
 251 WTNKNLIVVD DVRKSVHLYC FWKSENITPR MQHDTSHLFT TLGLRGLSGI  
 301 GAFRGMCTPH RSCAIVTFMN FTLGTFSIAV AHHLGHNLMG NHDEDTCRCS  
 351 QPRCIMHEGN PPITKFSNCS YGDFWEYTV ETKCLLET VH TKDIFNVKRC  
 401 GNGVVEEGEE CDCGPLKHCA KDPCCLSNCT LTDGSTCAFQ LCCCKDCKFLP  
 451 SGKVCERKEVN ECDLPEWCNG TSHKCPDDFY VEDGIPCKER GYCYEKSCHD  
 501 RNEQCCRIFG AGANTASETC YKELNTLGDR VGHCGIKNAT YIKCNISDVQ  
 551 CGRIQCENVT EIFNMSDHTT VHWARFNDIM CWSTDYHLGM KGPDIGEVKD  
 601 GTECGIDHIC IHEHCVHITI LNSNCSPAFC NKGICNNKH HCHCNYLWDP  
 651 PNCLIKGYGG SVDSGPPPKR EFKKKFCYLC ILLLVLFIL LCCLYRLCKK  
 701 SKPIKKQDDV QTPSAKEEEK IQRRPHELPP QSQPWVMPQ SQPPVTSPQ  
 751 QPQLMPSSQ PPVTPS\*

-16-

```

551 CGEIQCEHVT EIPNMSDHTT VHWAFENDIM CWSTDYHLGM KGPDIGEVED
601 GTECGIDHIC IHRHCVHITI LNSNCSPAFC NRGICNNKH HCHCNYLWDP
651 PNCLIEGYGG SVDSGPPPKR KKKKKFCYLC ILLLVLFIL LCCLYRLCKK
701 SKPIEKQQDV QTPSAKEEFQ IQEPHELPP QSQPWVMPSSQ SQPPVTPSQS
751 HPFVMPQSQ PPQNLFELEFE SIGCVLNEP LLYLOAT* (SEQ ID NO:13)

```

**Name: SVPH-1c (polypeptide)**

```

1 MFMLLLHCL GVFLSCSGHI QDEHPQYHSP PDVVIFVRIT GTTFGMTPFG
51 WLSYILPFGG QKHIIHIVF KLLFSKHLPV FTYTDQGAIL EDQPFVQNNC
101 YYHGYVEGDP ESLVSLSTCF GGFGILQIN DFAYEIKPLA FSTTFEHLVY
151 KMDSEEFQFS TMRSGFMONE ITCMEFEEI DNSTQKQSSY VGWVIHFRIV
201 EIVVVIDNYL YIRYERNDSK LLEDLYVIVN IVDSILDVIG VKVILFGLGI
251 WTNKNLIVVD DVEKSVHLYC FWKSENITPR MQHDTSHLFT TLGLFGLSGI
301 GAFRGMCTPH RSCAIVTFMN FTLGTFSIAV AHHLGHNLMG NHDEDTCFCS
351 QPFCIMHEGN PPITKFSNCS YGDFWEYTV ETKCLLET VH TEDIFNVKRC
401 GNGVVEEGEE CDCGPLEHCA KDPCLSNCT LTDGSTCAFG LCCKDCKFLP
451 SGIVCRHEVN ECDLPEWONG TSHKCFDDFY VEDGIFCKER GYCYEKSCHD
501 RNEQCREIFG AGANTASETC YKELNTLGDR VGHCGIKNAT YIKCHISDVQ
551 CGEIQCEHVT EIPNMSDHTT VHWAFENDIM CWSTDYHLGM KGPDIGEVED
601 GTECGIDHIC IHRHCVHITI LNSNCSPAFC NRGICNNKH HCHCNYLWDP
651 PNCLIEGYGG SVDSGPPPKR KKKKKFCYLC ILLLVLFIL LCCLYRLCKK
701 SKPIEKQQDV QTPSAKEEFQ IQEPHELPP QSQPWVMPSSQ SQPPVTPSQS
751 HPFVMPQSQ PPVMPQSQHP QLTPSQSQPP VMPQSQSHPQL TPSQSQPPVT
801 PSQRQPQLMP SQSQPPVTPS * (SEQ ID NO:14)

```

**Name: SVPH-4a (polypeptide)**

```

1 MRCVQIFLSQ CRLLLLLLVPT MLLKSLGEDV IFHPEGEFDS YEVTIPEKLS
51 FRGEVQGVVS PVSYLLQLKG KKHVLHLWPE RLLLPRIHLRV FSFTEHGELL
101 EDHPYIPFDC NYMGSVFESL DSKATISTCM GGLRGVFNID AKHYQIEPLF
151 ASPSEFHVY LLEKEQFGNQ VGLSDDEIE WQMAPYENKA FLRDFPGSYF
201 HPKYLELILL FDQSYEFVN NNLSQVIHDA ILLTGIMDTY FQDVRMFIHL
251 KALEVWTFEN KIEVGYELA EVLGRFVIYE KSVLNARLSS DWAHLYLQRE
301 YNDALAWSFG KVCSELYAGS VSTLDTNIL APATWSAHEL GHAVGMSHDE
351 QYCQCRGFN CIMSGRTGF SNCSYISFFE HISSGATCLN NIPGLGYVLE
401 RCGNKIVEDN EECDCGSTEE CQKDRCCQSN CKLQPGANCS IGLCHDCRF
451 RPSGYVCFQE GNECDLAEYC DGNSSSCPND VYKQDGTPOK YEGRCFRKGQ
501 PSRYMQCQSI FGPDAMEAPS EGYDAVNLIQ DQFGNCEITG IPNFRKCEGA
551 NSICGRLOCI NVETIPDLPE HTTIISTHLO AENLMCWGTG YHLSMKFMGI
601 PDLGMINDGT SCGESEVTEK EHCNHSVLQ EDCLPEKNT EGVNNRENE
651 HCMYGWAPPE CEEVGYGGS I DSGPPGLLRG AIPSSIWVVS IIMEPLILLL
701 LSVVVFVFRQ VIGNHLEPKQ EEMPLSKART QEESKTETV QEESKTETGQ
751 EESFAKTQEE ESKAKTGQEE SKAHIESKRP EAKSVKKQKK *
      (SEQ ID NO:15)

```

**Name: SVPH-4b (polypeptide)**

```

1 MRCVQIFLSQ CRLLLLLLVPT MLLKSLGEDV IFHPEGEFDS YEVTIPEKLS
51 FRGEVQGVVS PVSYLLQLKG KKHVLHLWPE RLLLPRIHLRV FSFTEHGELL
101 EDHPYIPFDC NYMGSVFESL DSKATISTCM GGLRGVFNID AKHYQIEPLF
151 ASPSEFHVY LLEKEQFGNQ VGLSDDEIE WQMAPYENKA FLRDFPGSYF
201 HPKYLELILL FDQSYEFVN NNLSQVIHDA ILLTGIMDTY FQDVRMFIHL

```



-17-

```

251 KALEVWTDEN KIRVGYPELA EVLGRFVIYK KSVLNARLSS DWAHLYLQRE
301 YNDALAWSEF KVCSELYAGS VETLLDTNIL APATWPAHEL GHAVGMSEHDE
351 QYCQCRGRIN CIMGSGRTGF SNCSYISFEK HISSGATCIN NIPGLGYVLF
401 KCGNKIVEDN EECDCGSTEK CQKDECCQSN CELQPGANCS IGLCCHDCKE
451 RPSGYVCRQE GNECDLAEYC DGNSSSCPND VYQDGTPECK YEGRCFREGC
501 RSRYMQCQSI FGPDAMEAPS EGYDAVNLIQ DQFGNCEITG IRNFKKCESA
551 NSICGELQCI NVETIPDLPE HTTIISTHLQ AENLMCWGTG YHLSMKPMGI
601 PDLGMINDGT SCGEGRVCFK KNCVNSSVLQ FDCLPEKCNT RGVCCNREKN
651 HCMYGWAPPF CEEVGYGGSY DSGPPGLLRG AIPSSIWVVS IIMFRLILLI
701 LSVVFVFFEQ VIGNHLEPKQ EKMPLSKAKT EQEESKTKTV QEESKTKTGQ
751 EESEAKTGQE ESKANIESKR PKAKSVKKQK K* (SEQ ID NO:16)

```

The discovery of the nucleic acids of the invention enables the construction of expression vectors comprising nucleic acid sequences encoding polypeptides; host cells transfected or transformed with the expression vectors; isolated and purified biologically active polypeptides and fragments thereof; the use of the nucleic acids or oligonucleotides thereof as probes to identify nucleic acid encoding proteins having metalloproteinase-disintegrin activity; the use of the nucleic acids or oligonucleotides thereof to identify human chromosome number 1 or 4; the use of the nucleic acids or oligonucleotides thereof to map genes on human chromosome number 1 or 4; the use of the nucleic acid or oligonucleotides thereof to identify genes associated with certain diseases, syndromes or other human conditions associated with human chromosome number 1 or 4, including fetal hydantoin syndrome, diphenylhydantoin toxicity, and pheochromocytoma; the use of single-stranded sense or antisense oligonucleotides from the nucleic acids to inhibit expression of polynucleotide encoded by the SVPH-1, SVPH-3, or SVPH-4 gene; the use of such polypeptides and soluble fragments to function as a proteinase; the use of such polypeptides and fragmented peptides as molecular weight markers; the use of such polypeptides and fragmented peptides as controls for peptide fragmentation, and kits comprising these reagents; the use of such polypeptides and fragments thereof to generate antibodies; and the use of antibodies to purify SVPH polypeptides.

### NUCLEIC ACID MOLECULES

In a particular embodiment, the invention relates to certain isolated nucleotide sequences that are free from contaminating endogenous material. A "nucleotide sequence" refers to a polynucleotide molecule in the form of a separate fragment or as a component of a larger nucleic acid construct. The nucleic acid molecule has been derived from DNA or RNA isolated at least once in substantially pure form and in a quantity or concentration enabling identification, manipulation, and recovery of its component nucleotide sequences by standard biochemical methods, such as those outlined in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989). Such sequences are preferably provided and/or constructed in the form of an open reading frame uninterrupted by internal non-translated sequences, or introns, that are typically present in eukaryotic genes. Sequences of non-translated DNA can be present 5' or 3' from an open reading frame, where the same do not interfere with manipulation or expression of the coding region.

Nucleic acid molecules of the invention include DNA in both single-stranded and double-stranded form, as well as the RNA complement thereof. DNA includes, for example, cDNA, genomic DNA, chemically synthesized DNA, DNA amplified by PCR, and combinations thereof. Genomic DNA may be isolated by conventional techniques, e.g., using the cDNA of SEQ ID NOs:1-3 and 7-11, or a suitable fragment thereof, as a probe.

The DNA molecules of the invention include full length genes as well as polynucleotides and fragments thereof. The full length gene may include the N-terminal signal peptide. Other embodiments include DNA encoding a soluble form, e.g., encoding the extracellular domain of the protein, either with or without the signal peptide.

The nucleic acids of the invention are preferentially derived from human sources, but the invention is not limited to human sources.

### Preferred Sequences

Particularly preferred nucleotide sequences of the invention are SEQ ID NOs:1-3 and 7-11, as set forth above. The sequences of amino acids encoded by the DNA of SEQ ID NOs:1-3 and 7-11 are shown in SEQ ID NOs:4-6 and 12-16, respectively. In SEQ ID NO:1 "N" can represent any nucleotide. These sequences identify the SVPH polynucleotides as members of the metalloproteinase-disintegrin family. As noted above, proteins of this family are characterized by a pro-domain, a disintegrin domain, a metalloproteinase domain, a cysteine rich region, a transmembrane domain, and a cytoplasmic tail.

In particular, SVPH-1 (originally isolated from human testis) and SVPH-4 (originally isolated from human testis, fetal lung, and B-cells) both share homology to the cysteine rich region of the metalloproteinase-disintegrin family, and SVPH-3 (originally isolated from human fetus tissue) shares homology to the pro-domain of these family members. In addition, SVPH-4 polypeptide (SEQ ID NO:3) encodes a zinc binding motif (His 47 to Asp 58), a disintegrin domain (Leu 104 to Cys 179), and a cysteine rich region (Asp 180 to Arg 388).

SVPH-1a, SVPH-1b, and SVPH-1c represent the nucleotide sequences (SEQ ID NOs:7-9) of three alternatively spliced SVPH-1 clones with divergent cytoplasmic domains. These clones were isolated by screening a human testis library (Clontech cat no. HL3024a) at 42°C and washing at 42°C in 2x SSC using four different oligonucleotides:

CACCTAAGGTGTTCAATTCTTTG (SEQ ID NO:17),  
CAAATACTGCAAGTGAGACTTGC (SEQ ID NO:18),  
TGCACAACCTACGTGTGGTGTACCC (SEQ ID NO:19), and  
GAGCCACTGCAATTGAAAAAGTGCCC (SEQ ID NO:20).

SVPH-4a and SVPH-4b represent the nucleotide sequences (SEQ ID NOs:10

and 11) of two alternatively spliced SVPH-4 clones with divergent cytoplasmic domains.

SVPH-4a and SVPH-4b were isolated by screening a human testis library (Clontech cat no. HL3024a) at 42°C and washing at 42°C in 2x SSC using four different oligonucleotides:

CTTTCACGGAGCCCATGTAGTTGCAG (SEQ ID NO:22), and  
TGAAGGAGAAAACGGCGCAGATGTCGG (SEQ ID NO:23).

#### Additional Sequences

Due to the known degeneracy of the genetic code, wherein more than one codon can encode the same amino acid, a DNA sequence can vary from that shown in SEQ ID NOs:1-3 and 7-11, and still encode a polypeptide having the amino acid sequence of SEQ ID NOs:4-6 and 12-16, respectively. Such variant DNA sequences can result from silent mutations (*e.g.*, occurring during PCR amplification), or can be the product of deliberate mutagenesis of a native sequence.

The invention thus provides isolated DNA sequences encoding polypeptides of the invention, selected from: (a) DNA comprising the nucleotide sequence of SEQ ID NOs:1-3 and 7-11; (b) DNA encoding the polypeptides of SEQ ID NOs:4-6 and 12-16; (c) DNA capable of hybridization to a DNA of (a) or (b) under conditions of moderate stringency and which encodes polypeptides of the invention; (d) DNA capable of hybridization to a DNA of (a) or (b) under conditions of high stringency and which encodes polypeptides of the invention, and (e) DNA which is degenerate as a result of the genetic code to a DNA defined in (a), (b), (c), or (d) and which encode polypeptides of the invention. Of course, polypeptides encoded by such DNA sequences are encompassed by the invention.

As used herein, conditions of moderate stringency can be readily determined by those having ordinary skill in the art based on, for example, the length of the DNA. The basic conditions are set forth by Sambrook et al. *Molecular Cloning: A Laboratory Manual*, 2nd ed. Vol. 1, pp. 1.101-104, Cold Spring Harbor Laboratory Press, (1989), and include use of a prewashing solution for the nitrocellulose filters 5X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0), hybridization conditions of about 50% formamide, 6X SSC at about 42°C (or other similar hybridization solution, such as

Generally, such conditions are defined as hybridization conditions as above, and with

washing at approximately 68°C, 0.2X SSC, 0.1% SDS. The skilled artisan will recognize that the temperature and wash solution salt concentration can be adjusted as necessary according to factors such as the length of the probe.

Also included as an embodiment of the invention is DNA encoding polypeptide fragments and polypeptides comprising inactivated N-glycosylation site(s), inactivated protease processing site(s), or conservative amino acid substitution(s), as described below.

In another embodiment, the nucleic acid molecules of the invention also comprise nucleotide sequences that are at least 80% identical to a native sequence. Also contemplated are embodiments in which a nucleic acid molecule comprises a sequence that is at least 90% identical, at least 95% identical, at least 98% identical, at least 99% identical, or at least 99.9% identical to a native sequence.

The percent identity may be determined by visual inspection and mathematical calculation. Alternatively, the percent identity of two nucleic acid sequences can be determined by comparing sequence information using the GAP computer program, version 6.0 described by Devereux et al., *Nucl. Acids Res.*, 12:387 (1984) and available from the University of Wisconsin Genetics Computer Group (UWGCG). The preferred default parameters for the GAP program include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) for nucleotides, and the weighted comparison matrix of Gribskov and Burgess, *Nucl. Acids Res.* 14:6745 (1986), as described by Schwartz and Dayhoff, eds., *Atlas of Protein Sequence and Structure*, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps. Other programs used by one skilled in the art of sequence comparison may also be used.

The invention also provides isolated nucleic acids useful in the production of polypeptides. Such polypeptides may be prepared by any of a number of conventional

or fragment. The DNA sequence advantageously is fused to a sequence encoding a suitable leader or signal peptide. Alternatively, the desired fragment may be

chemically synthesized using known techniques. DNA fragments also may be produced by restriction endonuclease digestion of a full length cloned DNA sequence, and isolated by electrophoresis on agarose gels. If necessary, oligonucleotides that reconstruct the 5' or 3' terminus to a desired point may be ligated to a DNA fragment generated by restriction enzyme digestion. Such oligonucleotides may additionally contain a restriction endonuclease cleavage site upstream of the desired coding sequence, and position an initiation codon (ATG) at the N-terminus of the coding sequence.

The well-known polymerase chain reaction (PCR) procedure also may be employed to isolate and amplify a DNA sequence encoding a desired protein fragment. Oligonucleotides that define the desired termini of the DNA fragment are employed as 5' and 3' primers. The oligonucleotides may additionally contain recognition sites for restriction endonucleases, to facilitate insertion of the amplified DNA fragment into an expression vector. PCR techniques are described in Saiki et al., *Science* 239:487 (1988); *Recombinant DNA Methodology*, Wu et al., eds., Academic Press, Inc., San Diego, pp. 189-196 (1989); and *PCR Protocols: A Guide to Methods and Applications*, Innis et al., eds., Academic Press, Inc. (1990).

#### POLYPEPTIDES AND FRAGMENTS THEREOF

The invention encompasses polypeptides and fragments thereof in various forms, including those that are naturally occurring or produced through various techniques such as procedures involving recombinant DNA technology. Such forms include, but are not limited to, derivatives, variants, and oligomers, as well as fusion proteins or fragments thereof.

##### Polypeptides and Fragments Thereof

The polypeptides of the invention include the proteins encoded by the nucleic acid sequences set forth above. Particularly preferred polypeptides comprise the

SEQUENCE IDENTIFICATION OF THE INVENTION

SEQ ID NO. 5 includes a pro domain homologous to the same family of protein.

SVPH-1 (SEQ ID NO:4) has an N-terminal region having amino acids Met 1 to Asn 40. In SEQ ID NO:4 "X" can represent any amino acid. SVPH-3 (SEQ ID NO:5) has an N-terminal region having amino acids Asn 1 to Leu 23. SVPH-4 (SEQ ID NO:6) also includes an extracellular domain comprising amino acids His 1 to Arg 388, a transmembrane region comprising amino acids Gly 389 through Phe 417, and a C-terminal cytoplasmic domain comprising amino acids Arg 418 to Lys 499 and is believed to overlap with EST designated AA 782936.

The SVPH-1a polypeptide (SEQ ID NO:12), SVPH-1b polypeptide (SEQ ID NO:13), and SVPH-1c polypeptide (SEQ ID NO:14) each encodes a signal sequence (Met 1 to Ser 15), a pro-domain (Cys 16 to Ser 188), a catalytic domain (Ser 189 to Thr 388), a disintegrin domain (Val 389 to Gly 491), a cysteine rich region (Tyr 492 to Lys 675), and a transmembrane domain (Phe 676 to Cys 698). In addition, each of the SVPH-1a, SVPH-1b, and SVPH-1c polypeptides (SEQ ID NOs:12-14) encodes a cytoplasmic domain. Due to alternative splicing the cytoplasmic domain of each polypeptide is different. For SVPH-1a, SVPH-1b, and SVPH-1c the cytoplasmic domains are (Lys 699 to Ser 766), (Lys 699 to Thr 787), and (Lys 699 to Ser 820), respectively.

Similarly, the SVPH-4a polypeptide (SEQ ID NO:15) and SVPH-4b polypeptide (SEQ ID NO:16) each encodes a signal sequence (Met 1 to Gly 27), a pro-domain (Glu 28 to Arg 193), a catalytic domain (Asp 194 to Ile 392), a disintegrin domain (Pro 393 to Gly 493), a cysteine rich region (Arg 494 to Ser 685), and a transmembrane domain (Ile 686 to Gly 713). In addition, each of the SVPH-4a and SVPH-4b polypeptides (SEQ ID NOs:15-16) encodes a cytoplasmic domain. Due to alternative splicing the cytoplasmic domain of each polypeptide is different. The cytoplasmic domain of SVPH-4a is (Asn 714 to Lys 790), and the cytoplasmic domain of SVPH-4b is (Asn 714 to Lys 781).

The skilled artisan will recognize that the above described boundaries of such

available for that purpose) may differ from those described above.

The polypeptides of the invention may be membrane bound or they may be

the cells in which they are expressed. In general, soluble polypeptides may be identified (and distinguished from non-soluble membrane-bound counterparts) by separating intact cells which express the desired polypeptide from the culture medium, e.g., by centrifugation, and assaying the medium (supernatant) for the presence of the desired polypeptide. The presence of polypeptide in the medium indicates that the polypeptide was secreted from the cells and thus is a soluble form of the protein.

In one embodiment, the soluble polypeptides and fragments thereof comprise all or part of the extracellular domain, but lack the transmembrane region that would cause retention of the polypeptide on a cell membrane. A soluble polypeptide may include the cytoplasmic domain, or a portion thereof, as long as the polypeptide is secreted from the cell in which it is produced.

In general, the use of soluble forms is advantageous for certain applications. Purification of the polypeptides from recombinant host cells is facilitated, since the soluble polypeptides are secreted from the cells. Further, soluble polypeptides are generally more suitable for intravenous administration.

The invention also provides polypeptides and fragments of the extracellular domain that retain a desired biological activity. Particular embodiments are directed to polypeptide fragments that retain the ability to bind the "binding partner" or the native cognates, substrates, or counter-structure. Such a fragment may be a soluble polypeptide, as described above. In another embodiment, the polypeptides and fragments advantageously include regions that are conserved in the SVPH family as described above.

Also provided herein are polypeptide fragments comprising at least 20, or at least 30, contiguous amino acids of the sequences of SEQ ID NOs:4-6 and 12-16. Fragments derived from the cytoplasmic domain find use in studies of signal transduction, and in regulating cellular processes associated with transduction of biological signals. Polypeptide fragments also may be employed as immunogens, in diagnostic assays, or as antibodies.

Naturally occurring variants as well as derived variants of the polypeptides and fragments are provided herein.



Variants may exhibit amino acid sequences that are at least 80% identical. Also contemplated are embodiments in which a polypeptide or fragment comprises an amino acid sequence that is at least 90% identical, at least 95% identical, at least 98% identical, at least 99% identical, or at least 99.9% identical to the preferred polypeptide or fragment thereof. Percent identity may be determined by visual inspection and mathematical calculation. Alternatively, the percent identity of two protein sequences can be determined by comparing sequence information using the GAP computer program, based on the algorithm of Needleman and Wunsch, *J. Mol. Biol.*, 48:443 (1970) and available from the University of Wisconsin Genetics Computer Group (UWGCG). The preferred default parameters for the GAP program include: (1) a scoring matrix, blosum62, as described by Henikoff and Henikoff, *Proc. Natl. Acad. Sci. USA*, 89:10915 (1992); (2) a gap weight of 12; (3) a gap length weight of 4; and (4) no penalty for end gaps. Other programs used by one skilled in the art of sequence comparison may also be used.

The variants of the invention include, for example, those that result from alternate mRNA splicing events or from proteolytic cleavage. Alternate splicing of mRNA may, for example, yield a truncated but biologically active protein, such as a naturally occurring soluble form of the protein. Variations attributable to proteolysis include, for example, differences in the N- or C-termini upon expression in different types of host cells, due to proteolytic removal of one or more terminal amino acids from the protein (generally from 1-5 terminal amino acids). Proteins in which differences in amino acid sequence are attributable to genetic polymorphism (allelic variation among individuals producing the protein) are also contemplated herein.

Additional variants within the scope of the invention include polypeptides that may be modified to create derivatives thereof by forming covalent or aggregative conjugates with other chemical moieties, such as glycosyl groups, lipids, phosphate, acetyl groups and the like. Covalent derivatives may be prepared by linking the

therapeutic agents attached thereto are contemplated herein, as discussed in more detail below.

Among the variant polypeptides provided herein are variants of native

Variants include polypeptides that are substantially homologous to the native

[illegible]

1. The first step is to identify the key components of the system. This includes understanding the hardware, software, and data involved.

Glu and Asp, or Gln and Asn; or substitutions of one aromatic residue for another, such as Phe, Trp, or Tyr for one another. Other conservative substitutions, *e.g.*, involving substitutions of entire regions having similar hydrophobicity characteristics, are well known.

Similarly, the DNAs of the invention include variants that differ from a native DNA sequence because of one or more deletions, insertions or substitutions, but that encode a biologically active polypeptide.

The invention further includes polypeptides of the invention with or without associated native-pattern glycosylation. Polypeptides expressed in yeast or mammalian expression systems (*e.g.*, COS-1 or COS-7 cells) can be similar to or significantly different from a native polypeptide in molecular weight and glycosylation pattern, depending upon the choice of expression system. Expression of polypeptides of the invention in bacterial expression systems, such as *E. coli*, provides non-glycosylated molecules. Further, a given preparation may include multiple differentially glycosylated species of the protein. Glycosyl groups can be removed through conventional methods, in particular those utilizing glycopeptidase. In general, glycosylated polypeptides of the invention can be incubated with a molar excess of glycopeptidase (Boehringer Mannheim).

Correspondingly, similar DNA constructs that encode various additions or substitutions of amino acid residues or sequences, or deletions of terminal or internal residues or sequences are encompassed by the invention. For example, N-glycosylation sites in the polypeptide extracellular domain can be modified to preclude glycosylation, allowing expression of a reduced carbohydrate analog in mammalian and yeast expression systems. N-glycosylation sites in eukaryotic polypeptides are characterized by an amino acid triplet Asn-X-Y, wherein X is any amino acid except Pro and Y is Ser or Thr. Appropriate substitutions, additions, or deletions to the nucleotide sequence encoding these triplets will result in prevention of

sufficient to inactivate an N-glycosylation site. Alternatively, the Ser or Thr can be replaced with another amino acid, such as Ala. Known procedures for the synthesis of

glycosylation sites in proteins include those described in U.S. Patent 5,071,972 and EP 276,846, hereby incorporated by reference.

In another example of variants, sequences encoding Cys residues that are not essential for biological activity can be altered to cause the Cys residues to be deleted or replaced with other amino acids, preventing formation of incorrect intramolecular disulfide bridges upon folding or renaturation.

Other variants are prepared by modification of adjacent dibasic amino acid residues, to enhance expression in yeast systems in which KEX2 protease activity is present. EP 212,914 discloses the use of site-specific mutagenesis to inactivate KEX2 protease processing sites in a protein. KEX2 protease processing sites are inactivated by deleting, adding or substituting residues to alter Arg-Arg, Arg-Lys, and Lys-Arg pairs to eliminate the occurrence of these adjacent basic residues. Lys-Lys pairings are considerably less susceptible to KEX2 cleavage, and conversion of Arg-Lys or Lys-Arg to Lys-Lys represents a conservative and preferred approach to inactivating KEX2 sites.

### Oligomers

Encompassed by the invention are oligomers or fusion proteins that contain SVPH polypeptides. When the polypeptide of the invention is a type I membrane protein, such as SVPH, the fusion partner is linked to the C terminus of the type I membrane protein. Such oligomers may be in the form of covalently-linked or non-covalently-linked multimers, including dimers, trimers, or higher oligomers. As noted above, preferred polypeptides are soluble and thus these oligomers may comprise soluble polypeptides. In one aspect of the invention, the oligomers maintain the binding ability of the polypeptide components and provide therefor, bivalent, trivalent, etc., binding sites.

One embodiment of the invention is directed to oligomers comprising multiple

copies of a polypeptide of the invention, such as a polypeptide of the invention as set forth

in Table 1. In one aspect, the polypeptide of the invention is a polypeptide of the invention

certain polypeptides derived from antibodies are among the peptides that can promote

oligomerization of the polypeptides attached thereto, as described in more detail below.

#### Immunoglobulin-based Oligomers

As one alternative, an oligomer is prepared using polypeptides derived from immunoglobulins. Preparation of fusion proteins comprising certain heterologous polypeptides fused to various portions of antibody-derived polypeptides (including the Fc domain) has been described, e.g., by Ashkenazi et al., *PNAS USA*, 88:10535 (1991); Byrn et al., *Nature*, 344:677 (1990); and Hollenbaugh and Aruffo, "Construction of Immunoglobulin Fusion Proteins", *Current Protocols in Immunology*, Suppl. 4, pages 10.19.1 - 10.19.11 (1992).

One embodiment of the present invention is directed to a dimer comprising two fusion proteins created by fusing a polypeptide of the invention to an Fc polypeptide derived from an antibody. A gene fusion encoding the polypeptide/Fc fusion protein is inserted into an appropriate expression vector. Polypeptide/Fc fusion proteins are expressed in host cells transformed with the recombinant expression vector, and allowed to assemble much like antibody molecules, whereupon interchain disulfide bonds form between the Fc moieties to yield divalent molecules.

The term "Fc polypeptide" as used herein includes native and mutein forms of polypeptides made up of the Fc region of an antibody comprising any or all of the CH domains of the Fc region. Truncated forms of such polypeptides containing the hinge region that promotes dimerization are also included. Preferred polypeptides comprise an Fc polypeptide derived from a human IgG1 antibody.

One suitable Fc polypeptide, described in PCT application WO 93/10151 (hereby incorporated by reference), is a single chain polypeptide extending from the N-terminal hinge region to the native C-terminus of the Fc region of a human IgG1 antibody. Another useful Fc polypeptide is the Fc mutein described in U.S. Patent 5,457,035 and in Baum et al., *EMBO J* 13:3992-4001 (1994), incorporated herein by

from Leu to Ala, amino acid 29 has been changed from Leu to Glu, and amino acid 32 has been changed from Gly to Ala. The mutein exhibits reduced affinity for Fc

The above-described fusion proteins comprising Fc moieties (and oligomers formed therefrom) offer the advantage of facile purification by affinity chromatography over Protein A or Protein G columns.

In other embodiments, the polypeptides of the invention may be substituted for the variable portion of an antibody heavy or light chain. If fusion proteins are made with both heavy and light chains of an antibody, it is possible to form an oligomer with as many as four SVPH extracellular regions.

#### Peptide-linker Based Oligomers

Alternatively, the oligomer is a fusion protein comprising multiple polypeptides, with or without peptide linkers (spacer peptides). Among the suitable peptide linkers are those described in U.S. Patents 4,751,180 and 4,935,233, which are hereby incorporated by reference. A DNA sequence encoding a desired peptide linker may be inserted between, and in the same reading frame as, the DNA sequences of the invention, using any suitable conventional technique. For example, a chemically synthesized oligonucleotide encoding the linker may be ligated between the sequences. In particular embodiments, a fusion protein comprises from two to four soluble SVPH polypeptides, separated by peptide linkers.

#### Leucine-Zippers

Another method for preparing the oligomers of the invention involves use of a leucine zipper. Leucine zipper domains are peptides that promote oligomerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., *Science*, 240:1759 (1988)), and have since been found in a variety of different proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize.

The zipper domain (also referred to herein as an oligomerizing, or oligomer-

found in rat liver, C-FBP, (Landschulz et al., *Science* 243:1681 (1989)). Two nuclear

product of the murine proto-oncogene, c-myc (Landschulz et al., *Science* 240:1759 (1988)). The zipper domains of *fos* and *jun* preferentially form heterodimer (O'Shea et al., *Science* 245:646 (1989), Turner and Tjian, *Science*, 243:1689 (1989)). The zipper domain is necessary for biological activity (DNA binding) in these proteins.

The fusogenic proteins of several different viruses, including paramyxovirus, coronavirus, measles virus and many retroviruses, also possess zipper domains (Buckland and Wild, *Nature* 338:547 (1989); Britton, *Nature*, 353:394 (1991); Delwart and Mosialos, *AIDS Research and Human Retroviruses* 6:703 (1990)). The zipper domains in these fusogenic viral proteins are near the transmembrane region of the proteins; it has been suggested that the zipper domains could contribute to the oligomeric structure of the fusogenic proteins. Oligomerization of fusogenic viral proteins is involved in fusion pore formation (Spruce et al., *Proc. Natl. Acad. Sci. U.S.A.*, 88:3523 (1991)). Zipper domains have also been recently reported to play a role in oligomerization of heat-shock transcription factors (Rabindran et al., *Science* 259:230 (1993)).

Zipper domains fold as short, parallel coiled coils (O'Shea et al., *Science* 254:539 (1991)). The general architecture of the parallel coiled coil has been well characterized, with a "knobs-into-holes" packing as proposed by Crick, *Acta Crystallogr.*, 6:689 (1953). The dimer formed by a zipper domain is stabilized by the heptad repeat, designated  $(abcdefg)_n$  according to the notation of McLachlan and Stewart, *J. Mol. Biol.*, 98:293 (1975), in which residues *a* and *d* are generally hydrophobic residues, with *d* being a leucine, which line up on the same face of a helix. Oppositely-charged residues commonly occur at positions *g* and *e*. Thus, in a parallel coiled coil formed from two helical zipper domains, the "knobs" formed by the hydrophobic side chains of the first helix are packed into the "holes" formed between the side chains of the second helix.

It is well known that the zipper domain is a common motif in proteins.

For example, in the field of protein structure, the zipper domain has been reported the synthesis of a triple-stranded  $\alpha$ -helical bundle in which the helices run parallel to each other. In this structure, the zipper domain is formed by the hydrophobic side chains of the first helix are packed into the "holes" formed between the side chains of the second helix.

studies also indicate that electrostatic interactions contribute to the stoichiometry and geometry of coiled coils. Further discussion of the structure of leucine zippers is found in Harbury et al., *Science*, 262:1401 (1993).

Examples of leucine zipper domains suitable for producing soluble oligomeric proteins are described in PCT application WO 94/10308, as well as the leucine zipper derived from lung surfactant protein D (SPD) described in Hoppe et al., *FEBS Letters*, 344:191 (1994), hereby incorporated by reference. The use of a modified leucine zipper that allows for stable trimerization of a heterologous protein fused thereto is described in Fanslow et al., *Semin. Immunol.*, 6:267-278 (1994). Recombinant fusion proteins comprising a soluble polypeptide fused to a leucine zipper peptide are expressed in suitable host cells, and the soluble oligomer that forms is recovered from the culture supernatant.

Certain leucine zipper moieties preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD) noted above, as described in Hoppe et al., *FEBS Letters*, 344:191 (1994) and in U.S. Patent 5,716,805, hereby incorporated by reference in their entirety. This lung SPD-derived leucine zipper peptide comprises the amino acid sequence Pro Asp Val Ala Ser Leu Arg Gln Gln Val Glu Ala Leu Gln Gly Gln Val Gln His Leu Gln Ala Ala Phe Ser Gln Tyr (SEQ ID NO:29).

Another example of a leucine zipper that promotes trimerization is a peptide comprising the amino acid sequence Arg Met Lys Gln Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr His Ile Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu Arg (SEQ ID NO:30), as described in U.S. Patent 5,716,805. In one alternative embodiment, an N-terminal Asp residue is added; in another, the peptide lacks the N-terminal Arg residue.

Fragments of the foregoing zipper peptides that retain the property of promoting oligomerization may be employed as well. Examples of such fragments

include those in which one or more of the amino acid residues (or the amino acid side chain substitution(s)) in the native amino acid sequence, wherein the peptide's ability to



Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric SVPH. Alternatively, synthetic peptides that promote oligomerization may be employed. In particular embodiments, leucine residues in a leucine zipper moiety are replaced by isoleucine residues. Such peptides comprising isoleucine may be referred to as isoleucine zippers, but are encompassed by the term "leucine zippers" as employed herein.

### PRODUCTION OF POLYPEPTIDES AND FRAGMENTS THEREOF

Expression, isolation and purification of the polypeptides and fragments of the invention may be accomplished by any suitable technique, including but not limited to the following:

#### Expression Systems

The present invention also provides recombinant cloning and expression vectors containing DNA, as well as host cell containing the recombinant vectors. Expression vectors comprising DNA may be used to prepare the polypeptides or fragments of the invention encoded by the DNA. A method for producing polypeptides comprises culturing host cells transformed with a recombinant expression vector encoding the polypeptide, under conditions that promote expression of the polypeptide, then recovering the expressed polypeptides from the culture. The skilled artisan will recognize that the procedure for purifying the expressed polypeptides will vary according to such factors as the type of host cells employed, and whether the polypeptide is membrane-bound or a soluble form that is secreted from the host cell.

Any suitable expression system may be employed. The vectors include a DNA encoding a polypeptide or fragment of the invention, operably linked to suitable transcriptional or translational regulatory nucleotide sequences, such as those derived

ribosomal binding site, and appropriate sequences which control transcription and translation initiation and termination. Nucleotide sequences are operably linked to a

In addition, a sequence encoding an appropriate signal peptide (native or heterologous) can be incorporated into expression vectors. A DNA sequence for a signal peptide (secretory leader) may be fused in frame to the nucleic acid sequence of the invention so that the DNA is initially transcribed, and the mRNA translated, into a fusion protein comprising the signal peptide. A signal peptide that is functional in the intended host cells promotes extracellular secretion of the polypeptide. The signal peptide is cleaved from the polypeptide upon secretion of polypeptide from the cell.

Suitable host cells for expression of polypeptides include prokaryotes, yeast or higher eukaryotic cells. Mammalian or insect cells are generally preferred for use as host cells. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are described, for example, in Pouwels et al. *Cloning Vectors: A Laboratory Manual*, Elsevier, New York, (1985). Cell-free translation systems could also be employed to produce polypeptides using RNAs derived from DNA constructs disclosed herein.

1. The first group of variables, *demographics*, includes age, sex, and marital status. The second group, *education*, includes years of schooling, high school graduation, and college graduation. The third group, *employment*, includes employment status, occupation, and industry. The fourth group, *income*, includes household income and personal income. The fifth group, *housing*, includes home ownership, home value, and home age. The sixth group, *transportation*, includes car ownership and car age. The seventh group, *leisure*, includes leisure time and leisure activities. The eighth group, *health*, includes health status and health insurance. The ninth group, *social*, includes social network and social support. The tenth group, *psychological*, includes psychological well-being and psychological distress. The eleventh group, *environmental*, includes environmental quality and environmental concern. The twelfth group, *community*, includes community involvement and community satisfaction. The thirteenth group, *quality of life*, includes quality of life and life satisfaction. The fourteenth group, *well-being*, includes well-being and happiness. The fifteenth group, *life satisfaction*, includes life satisfaction and life expectancy. The sixteenth group, *life expectancy*, includes life expectancy and life expectancy at birth. The seventeenth group, *life expectancy at birth*, includes life expectancy at birth and life expectancy at age 65. The eighteenth group, *life expectancy at age 65*, includes life expectancy at age 65 and life expectancy at age 75. The nineteenth group, *life expectancy at age 75*, includes life expectancy at age 75 and life expectancy at age 85. The twentieth group, *life expectancy at age 85*, includes life expectancy at age 85 and life expectancy at age 95. The twenty-first group, *life expectancy at age 95*, includes life expectancy at age 95 and life expectancy at age 100. The twenty-second group, *life expectancy at age 100*, includes life expectancy at age 100 and life expectancy at age 105. The twenty-third group, *life expectancy at age 105*, includes life expectancy at age 105 and life expectancy at age 110. The twenty-fourth group, *life expectancy at age 110*, includes life expectancy at age 110 and life expectancy at age 115. The twenty-fifth group, *life expectancy at age 115*, includes life expectancy at age 115 and life expectancy at age 120. The twenty-sixth group, *life expectancy at age 120*, includes life expectancy at age 120 and life expectancy at age 125. The twenty-seventh group, *life expectancy at age 125*, includes life expectancy at age 125 and life expectancy at age 130. The twenty-eighth group, *life expectancy at age 130*, includes life expectancy at age 130 and life expectancy at age 135. The twenty-ninth group, *life expectancy at age 135*, includes life expectancy at age 135 and life expectancy at age 140. The thirtieth group, *life expectancy at age 140*, includes life expectancy at age 140 and life expectancy at age 145. The thirty-first group, *life expectancy at age 145*, includes life expectancy at age 145 and life expectancy at age 150. The thirty-second group, *life expectancy at age 150*, includes life expectancy at age 150 and life expectancy at age 155. The thirty-third group, *life expectancy at age 155*, includes life expectancy at age 155 and life expectancy at age 160. The thirty-fourth group, *life expectancy at age 160*, includes life expectancy at age 160 and life expectancy at age 165. The thirty-fifth group, *life expectancy at age 165*, includes life expectancy at age 165 and life expectancy at age 170. The thirty-sixth group, *life expectancy at age 170*, includes life expectancy at age 170 and life expectancy at age 175. The thirty-seventh group, *life expectancy at age 175*, includes life expectancy at age 175 and life expectancy at age 180. The thirty-eighth group, *life expectancy at age 180*, includes life expectancy at age 180 and life expectancy at age 185. The thirty-ninth group, *life expectancy at age 185*, includes life expectancy at age 185 and life expectancy at age 190. The fortieth group, *life expectancy at age 190*, includes life expectancy at age 190 and life expectancy at age 195. The forty-first group, *life expectancy at age 195*, includes life expectancy at age 195 and life expectancy at age 200. The forty-second group, *life expectancy at age 200*, includes life expectancy at age 200 and life expectancy at age 205. The forty-third group, *life expectancy at age 205*, includes life expectancy at age 205 and life expectancy at age 210. The forty-fourth group, *life expectancy at age 210*, includes life expectancy at age 210 and life expectancy at age 215. The forty-fifth group, *life expectancy at age 215*, includes life expectancy at age 215 and life expectancy at age 220. The forty-sixth group, *life expectancy at age 220*, includes life expectancy at age 220 and life expectancy at age 225. The forty-seventh group, *life expectancy at age 225*, includes life expectancy at age 225 and life expectancy at age 230. The forty-eighth group, *life expectancy at age 230*, includes life expectancy at age 230 and life expectancy at age 235. The forty-ninth group, *life expectancy at age 235*, includes life expectancy at age 235 and life expectancy at age 240. The fiftieth group, *life expectancy at age 240*, includes life expectancy at age 240 and life expectancy at age 245. The fifty-first group, *life expectancy at age 245*, includes life expectancy at age 245 and life expectancy at age 250. The fifty-second group, *life expectancy at age 250*, includes life expectancy at age 250 and life expectancy at age 255. The fifty-third group, *life expectancy at age 255*, includes life expectancy at age 255 and life expectancy at age 260. The fifty-fourth group, *life expectancy at age 260*, includes life expectancy at age 260 and life expectancy at age 265. The fifty-fifth group, *life expectancy at age 265*, includes life expectancy at age 265 and life expectancy at age 270. The fifty-sixth group, *life expectancy at age 270*, includes life expectancy at age 270 and life expectancy at age 275. The fifty-seventh group, *life expectancy at age 275*, includes life expectancy at age 275 and life expectancy at age 280. The fifty-eighth group, *life expectancy at age 280*, includes life expectancy at age 280 and life expectancy at age 285. The fifty-ninth group, *life expectancy at age 285*, includes life expectancy at age 285 and life expectancy at age 290. The sixtieth group, *life expectancy at age 290*, includes life expectancy at age 290 and life expectancy at age 295. The sixty-first group, *life expectancy at age 295*, includes life expectancy at age 295 and life expectancy at age 300. The sixty-second group, *life expectancy at age 300*, includes life expectancy at age 300 and life expectancy at age 305. The sixty-third group, *life expectancy at age 305*, includes life expectancy at age 305 and life expectancy at age 310. The sixty-fourth group, *life expectancy at age 310*, includes life expectancy at age 310 and life expectancy at age 315. The sixty-fifth group, *life expectancy at age 315*, includes life expectancy at age 315 and life expectancy at age 320. The sixty-sixth group, *life expectancy at age 320*, includes life expectancy at age 320 and life expectancy at age 325. The sixty-seventh group, *life expectancy at age 325*, includes life expectancy at age 325 and life expectancy at age 330. The sixty-eighth group, *life expectancy at age 330*, includes life expectancy at age 330 and life expectancy at age 335. The sixty-ninth group, *life expectancy at age 335*, includes life expectancy at age 335 and life expectancy at age 340. The seventieth group, *life expectancy at age 340*, includes life expectancy at age 340 and life expectancy at age 345. The seventy-first group, *life expectancy at age 345*, includes life expectancy at age 345 and life expectancy at age 350. The seventy-second group, *life expectancy at age 350*, includes life expectancy at age 350 and life expectancy at age 355. The seventy-third group, *life expectancy at age 355*, includes life expectancy at age 355 and life expectancy at age 360. The seventy-fourth group, *life expectancy at age 360*, includes life expectancy at age 360 and life expectancy at age 365. The seventy-fifth group, *life expectancy at age 365*, includes life expectancy at age 365 and life expectancy at age 370. The seventy-sixth group, *life expectancy at age 370*, includes life expectancy at age 370 and life expectancy at age 375. The seventy-seventh group, *life expectancy at age 375*, includes life expectancy at age 375 and life expectancy at age 380. The seventy-eighth group, *life expectancy at age 380*, includes life expectancy at age 380 and life expectancy at age 385. The seventy-ninth group, *life expectancy at age 385*, includes life expectancy at age 385 and life expectancy at age 390. The eightieth group, *life expectancy at age 390*, includes life expectancy at age 390 and life expectancy at age 395. The eighty-first group, *life expectancy at age 395*, includes life expectancy at age 395 and life expectancy at age 400. The eighty-second group, *life expectancy at age 400*, includes life expectancy at age 400 and life expectancy at age 405. The eighty-third group, *life expectancy at age 405*, includes life expectancy at age 405 and life expectancy at age 410. The eighty-fourth group, *life expectancy at age 410*, includes life expectancy at age 410 and life expectancy at age 415. The eighty-fifth group, *life expectancy at age 415*, includes life expectancy at age 415 and life expectancy at age 420. The eighty-sixth group, *life expectancy at age 420*, includes life expectancy at age 420 and life expectancy at age 425. The eighty-seventh group, *life expectancy at age 425*, includes life expectancy at age 425 and life expectancy at age 430. The eighty-eighth group, *life expectancy at age 430*, includes life expectancy at age 430 and life expectancy at age 435. The eighty-ninth group, *life expectancy at age 435*, includes life expectancy at age 435 and life expectancy at age 440. The ninetieth group, *life expectancy at age 440*, includes life expectancy at age 440 and life expectancy at age 445. The ninety-first group, *life expectancy at age 445*, includes life expectancy at age 445 and life expectancy at age 450. The ninety-second group, *life expectancy at age 450*, includes life expectancy at age 450 and life expectancy at age 455. The ninety-third group, *life expectancy at age 455*, includes life expectancy at age 455 and life expectancy at age 460. The ninety-fourth group, *life expectancy at age 460*, includes life expectancy at age 460 and life expectancy at age 465. The ninety-fifth group, *life expectancy at age 465*, includes life expectancy at age 465 and life expectancy at age 470. The ninety-sixth group, *life expectancy at age 470*, includes life expectancy at age 470 and life expectancy at age 475. The ninety-seventh group, *life expectancy at age 475*, includes life expectancy at age 475 and life expectancy at age 480. The ninety-eighth group, *life expectancy at age 480*, includes life expectancy at age 480 and life expectancy at age 485. The ninety-ninth group, *life expectancy at age 485*, includes life expectancy at age 485 and life expectancy at age 490. The hundredth group, *life expectancy at age 490*, includes life expectancy at age 490 and life expectancy at age 495. The hundred-first group, *life expectancy at age 495*, includes life expectancy at age 495 and life expectancy at age 500. The hundred-second group, *life expectancy at age 500*, includes life expectancy at age 500 and life expectancy at age 505. The hundred-third group, *life expectancy at age 505*, includes life expectancy at age 505 and life expectancy at age 510. The hundred-fourth group, *life expectancy at age 510*, includes life expectancy at age 510 and life expectancy at age 515. The hundred-fifth group, *life expectancy at age 515*, includes life expectancy at age 515 and life expectancy at age 520. The hundred-sixth group, *life expectancy at age 520*, includes life expectancy at age 520 and life expectancy at age 525. The hundred-seventh group, *life expectancy at age 525*, includes life expectancy at age 525 and life expectancy at age 530. The hundred-eighth group, *life expectancy at age 530*, includes life expectancy at age 530 and life expectancy at age 535. The hundred-ninth group, *life expectancy at age 535*, includes life expectancy at age 535 and life expectancy at age 540. The hundred-tenth group, *life expectancy at age 540*, includes life expectancy at age 540 and life expectancy at age 545. The hundred-eleventh group, *life expectancy at age 545*, includes life expectancy at age 545 and life expectancy at age 550. The hundred-twelfth group, *life expectancy at age 550*, includes life expectancy at age 550 and life expectancy at age 555. The hundred-thirteenth group, *life expectancy at age 555*, includes life expectancy at age 555 and life expectancy at age 560. The hundred-fourteenth group, *life expectancy at age 560*, includes life expectancy at age 560 and life expectancy at age 56

*Pseudomonas*, *Streptomyces*, and *Staphylococcus*. In a prokaryotic host cell, such as *Escherichia coli*, the expression of a recombinant protein is often achieved by the use of a

expression of the recombinant polypeptide in the prokaryotic host cell. The N-terminal Met may be cleaved from the expressed recombinant polypeptide.

Expression vectors for use in prokaryotic host cells generally comprise one or more phenotypic selectable marker genes. A phenotypic selectable marker gene is, for example, a gene encoding a protein that confers antibiotic resistance or that supplies an autotrophic requirement. Examples of useful expression vectors for prokaryotic host cells include those derived from commercially available plasmids such as the cloning vector pBR322 (ATCC 37017). pBR322 contains genes for ampicillin and tetracycline resistance and thus provides simple means for identifying transformed cells. An appropriate promoter and a DNA sequence are inserted into the pBR322 vector. Other commercially available vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEM1 (Promega Biotec, Madison, WI, USA).

Promoter sequences commonly used for recombinant prokaryotic host cell expression vectors include  $\beta$ -lactamase (penicillinase), lactose promoter system (Chang et al., *Nature*, 275:615 (1978); and Goeddel et al., *Nature*, 281:544 (1979)), tryptophan (trp) promoter system (Goeddel et al., *Nucl. Acids Res.*, 8:4057 (1980)); and EP-A-36776 and tac promoter (Maniatis, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, p. 412 (1982)). A particularly useful prokaryotic host cell expression system employs a phage  $\lambda P_L$  promoter and a cI857ts thermolabile repressor sequence. Plasmid vectors available from the American Type Culture Collection which incorporate derivatives of the  $\lambda P_L$  promoter include plasmid pHUB2 (resident in *E. coli* strain JMB9, ATCC 37092) and pPLc28 (resident in *E. coli* RR1, ATCC 53082).

### Yeast Systems

Alternatively, the polypeptide can be expressed in a yeast host cell, such as *S. cerevisiae*.

For expression in yeast, the expression vector may include a yeast origin of replication sequence from a 2 $\mu$  yeast plasmid, an autonomously replicating vector (APV), a yeast promoter sequence, and a yeast transcription start site.

for yeast vectors include, among others, promoters for metallothionein, 3-phosphoglycerate kinase (Hitzeman et al., *J. Biol. Chem.* 255:2073 (1980)) or other glycolytic enzymes (Hess et al., *J. Adv. Enzyme Reg.* 7:149 (1968); and Holland et al., *Biochem.* 17:4900 (1978)), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phospho-glucose isomerase, and glucokinase. Other suitable vectors and promoters for use in yeast expression are further described in Hitzeman, EPA-73,657. Another alternative is the glucose-repressible ADH2 promoter described by Russell et al., *J. Biol. Chem.*, 258:2674 (1982) and Beier et al., *Nature*, 300:724 (1982). Shuttle vectors replicable in both yeast and *E. coli* may be constructed by inserting DNA sequences from pBR322 for selection and replication in *E. coli* (Amp<sup>r</sup> gene and origin of replication) into the above-described yeast vectors.

The yeast  $\alpha$ -factor leader sequence may be employed to direct secretion of the polypeptide. The  $\alpha$ -factor leader sequence is often inserted between the promoter sequence and the structural gene sequence. See, Kurjan et al., *Cell*, 30:933 (1982) and Bitter et al., *Proc. Natl. Acad. Sci. USA*, 81:5330 (1984). Other leader sequences suitable for facilitating secretion of recombinant polypeptides from yeast hosts are known to those of skill in the art. A leader sequence may be modified near its 3' end to contain one or more restriction sites. This will facilitate fusion of the leader sequence to the structural gene.

Yeast transformation protocols are known to those of skill in the art. One such protocol is described by Hinnen et al., *Proc. Natl. Acad. Sci. USA*, 75:1929 (1978). The Hinnen et al. protocol selects for Trp<sup>r</sup> transformants in a selective medium, wherein the selective medium consists of 0.67% yeast nitrogen base, 0.5% casamino acids, 2% glucose, 10 mg/ml adenine and 20 mg/ml uracil.

Yeast host cells transformed by vectors containing an ADH2 promoter

are grown in a medium containing glucose. The ADH2 promoter is repressed by glucose.

When the glucose in the medium is exhausted, the ADH2 promoter occurs when glucose is exhausted from the medium

### Mammalian or Insect Systems

Mammalian or insect host cell culture systems also may be employed to express recombinant polypeptides. Bacculovirus systems for production of heterologous proteins in insect cells are reviewed by Luckow and Summers, *Bio/Technology* 6:47 (1988). Established cell lines of mammalian origin also may be employed. Examples of suitable mammalian host cell lines include the COS-7 line of monkey kidney cells (ATCC CRL 1651) (Gluzman et al., *Cell* 23:175 (1981)), L cells, C127 cells, 3T3 cells (ATCC CCL 163), Chinese hamster ovary (CHO) cells, HeLa cells, and BHK (ATCC CRL 10) cell lines, and the CV1/EBNA cell line derived from the African green monkey kidney cell line CV1 (ATCC CCL 70) as described by McMahan et al., *EMBO J.* 10: 2821 (1991).

Established methods for introducing DNA into mammalian cells have been described (Kaufman, R.J., *Large Scale Mammalian Cell Culture*, pp. 15-69 (1990)). Additional protocols using commercially available reagents, such as Lipofectamine lipid reagent (Gibco/BRL) or Lipofectamine-Plus lipid reagent, can be used to transfect cells (Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413-7417 (1987)). In addition, electroporation can be used to transfect mammalian cells using conventional procedures, such as those in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd ed. Vol. 1-3, Cold Spring Harbor Laboratory Press (1989). Selection of stable transformants can be performed using methods known in the art, such as, for example, resistance to cytotoxic drugs. Kaufman et al., *Meth. in Enzymology* 185:487-511 (1990), describes several selection schemes, such as dihydrofolate reductase (DHFR) resistance. A suitable host strain for DHFR selection can be CHO strain DX-B11, which is deficient in DHFR (Urlaub and Chasin, *Proc. Natl. Acad. Sci. USA* 77:4216-4220 (1980)). A plasmid expressing the DHFR cDNA can be introduced into strain DX-B11, and only cells that contain the plasmid can grow in the appropriate selective media. Other examples of selectable markers that can be

selected on the basis of resistance to these compounds.

Transcription and translational control sequences for mammalian cells are

sequences and enhancer sequences are derived from polyoma virus, adenovirus 2, simian virus 40 (SV40), and human cytomegalovirus. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early and late promoter, enhancer, splice, and polyadenylation sites can be used to provide other genetic elements for expression of a structural gene sequence in a mammalian host cell. Viral early and late promoters are particularly useful because both are easily obtained from a viral genome as a fragment, which can also contain a viral origin of replication (Fiers et al., *Nature* 273:113 (1978); Kaufman et al., *Meth. in Enzymology* 185:487-511 (1990)). Smaller or larger SV40 fragments can also be used, provided the approximately 250 bp sequence extending from the *Hind* III site toward the *Bgl* I site located in the SV40 viral origin of replication site is included.

Additional control sequences shown to improve expression of heterologous genes from mammalian expression vectors include such elements as the expression augmenting sequence element (EASE) derived from CHO cells (Morris et al., *Animal Cell Technology*, pp. 529-534 (1997)) and PCT Application WO 97/25420 and the tripartite leader (TPL) and VA gene RNAs from Adenovirus 2 (Gingras et al., *J. Biol. Chem.* 257:13475-13491 (1982)). The internal ribosome entry site (IRES) sequences of viral origin allows dicistronic mRNAs to be translated efficiently (Oh and Sarnow, *Current Opinion in Genetics and Development* 3:295-300 (1993); Ramesh et al., *Nucleic Acids Research* 24:2697-2700 (1996)). Expression of a heterologous cDNA as part of a dicistronic mRNA followed by the gene for a selectable marker (e.g. DHFR) has been shown to improve transfectability of the host and expression of the heterologous cDNA (Kaufman et al., *Meth. in Enzymology* 185:487-511 (1990)). Exemplary expression vectors that employ dicistronic mRNAs are pTR-DC/GFP described by Mosser et al., *Biotechniques* 22:150-161 (1997), and p2A5I described by Morris et al., *Animal Cell Technology*, pp. 529-534 (1997).

A useful high expression vector, pCAVNOT, has been described by Mosley et al., *Gene* 187:237-240 (1995). Other expression vectors are known in the art.

Transfected cells, including but not limited to murine mammary epithelial cells, can be constructed substantially as described by

PM1.SV N1/N4, described by Cosman et al., *Nature* 312:768 (1984), has been deposited as ATCC 39890. Additional useful mammalian expression vectors are described in EP-A-0367566, and in WO 91/18982, incorporated by reference herein. In yet another alternative, the vectors can be derived from retroviruses.

Additional useful expression vectors, pFLAG<sup>®</sup> and pDC311, can also be used. FLAG<sup>®</sup> technology is centered on the fusion of a low molecular weight (1kD), hydrophilic, FLAG<sup>®</sup> marker peptide to the N-terminus of a recombinant protein expressed by pFLAG<sup>®</sup> expression vectors. pDC311 is another specialized vector used for expressing proteins in CHO cells. pDC311 is characterized by a bicistronic sequence containing the gene of interest and a dihydrofolate reductase (DHFR) gene with an internal ribosome binding site for DHFR translation, an expression augmenting sequence element (EASE), the human CMV promoter, a tripartite leader sequence, and a polyadenylation site.

Regarding signal peptides that may be employed, the native signal peptide may be replaced by a heterologous signal peptide or leader sequence, if desired. The choice of signal peptide or leader may depend on factors such as the type of host cells in which the recombinant polypeptide is to be produced. To illustrate, examples of heterologous signal peptides that are functional in mammalian host cells include the signal sequence for interleukin-7 (IL-7) described in United States Patent 4,965,195; the signal sequence for interleukin-2 receptor described in Cosman et al., *Nature*, 312:768 (1984); the interleukin-4 receptor signal peptide described in EP 367,566; the type I interleukin-1 receptor signal peptide described in U.S. Patent 4,968,607; and the type II interleukin-1 receptor signal peptide described in EP 460,846.

### Purification

The invention also includes methods of isolating and purifying the

### Isolation and Purification

The "isolated" polypeptides or fragments thereof encompassed by this invention are polypeptides or fragments that are not in an environment identical to an environment in which it or they can be found in nature. The "purified" polypeptides or fragments thereof encompassed by this invention are essentially free of association with other proteins or polypeptides, for example, as a purification product of recombinant expression systems such as those described above or as a purified product from a non-recombinant source such as naturally occurring cells and/or tissues.

In one preferred embodiment, the purification of recombinant polypeptides or fragments can be accomplished using fusions of polypeptides or fragments of the invention to another polypeptide to aid in the purification of polypeptides or fragments of the invention. Such fusion partners can include the poly-His or other antigenic identification peptides described above as well as the Fc moieties described previously.

With respect to any type of host cell, as is known to the skilled artisan, procedures for purifying a recombinant polypeptide or fragment will vary according to such factors as the type of host cells employed and whether or not the recombinant polypeptide or fragment is secreted into the culture medium.

In general, the recombinant polypeptide or fragment can be isolated from the host cells if not secreted, or from the medium or supernatant if soluble and secreted, followed by one or more concentration, salting-out, ion exchange, hydrophobic interaction, affinity purification or size exclusion chromatography steps. As to specific ways to accomplish these steps, the culture medium first can be concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Following the concentration step, the concentrate can be applied to a purification matrix such as a gel filtration medium. Alternatively, an anion exchange resin can be employed, for example, a matrix or

purification. Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various ionizable matrices, comprising carboxylic, etc.



carboxymethyl groups. In addition, a chromatofocusing step can be employed. Alternatively, a hydrophobic interaction chromatography step can be employed. Suitable matrices can be phenyl or octyl moieties bound to resins. In addition, affinity chromatography with a matrix which selectively binds the recombinant protein can be employed. Examples of such resins employed are lectin columns, dye columns, and metal-chelating columns. Finally, one or more reversed-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, (e.g., silica gel or polymer resin having pendant methyl, octyl, octyldecyl or other aliphatic groups) can be employed to further purify the polypeptides. Some or all of the foregoing purification steps, in various combinations, are well known and can be employed to provide an isolated and purified recombinant protein.

It is also possible to utilize an affinity column comprising a polypeptide-binding protein of the invention, such as a monoclonal antibody generated against polypeptides of the invention, to affinity-purify expressed polypeptides. These polypeptides can be removed from an affinity column using conventional techniques, e.g., in a high salt elution buffer and then dialyzed into a lower salt buffer for use or by changing pH or other components depending on the affinity matrix utilized, or be competitively removed using the naturally occurring substrate of the affinity moiety, such as a polypeptide derived from the invention.

In this aspect of the invention, polypeptide-binding proteins, such as the anti-polypeptide antibodies of the invention or other proteins that may interact with the polypeptide of the invention, can be bound to a solid phase support such as a column chromatography matrix or a similar substrate suitable for identifying, separating, or purifying cells that express polypeptides of the invention on their surface. Adherence of polypeptide-binding proteins of the invention to a solid phase contacting surface can be accomplished by any means, for example, magnetic microspheres can be coated with these polypeptide-binding proteins and held in the incubation vessel

of the invention on their surface bind to the fixed polypeptide binding protein and unbound cells then are washed away. This affinity binding method is useful for

Methods of releasing positively selected cells from the solid phase are known in the art and encompass, for example, the use of enzymes. Such enzymes are preferably non-toxic and non-injurious to the cells and are preferably directed to cleaving the cell-surface binding partner.

Alternatively, mixtures of cells suspected of containing polypeptide-expressing cells of the invention first can be incubated with a biotinylated polypeptide-binding protein of the invention. Incubation periods are typically at least one hour in duration to ensure sufficient binding to polypeptides of the invention. The resulting mixture then is passed through a column packed with avidin-coated beads, whereby the high affinity of biotin for avidin provides the binding of the polypeptide-binding cells to the beads. Use of avidin-coated beads is known in the art. *See*, Berenson, et al., *J. Cell. Biochem.*, 10D:239 (1986). Wash of unbound material and the release of the bound cells is performed using conventional methods.

The desired degree of purity depends on the intended use of the protein. A relatively high degree of purity is desired when the polypeptide is to be administered *in vivo*, for example. In such a case, the polypeptides are purified such that no protein bands corresponding to other proteins are detectable upon analysis by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). It will be recognized by one skilled in the pertinent field that multiple bands corresponding to the polypeptide may be visualized by SDS-PAGE, due to differential glycosylation, differential post-translational processing, and the like. Most preferably, the polypeptide of the invention is purified to substantial homogeneity, as indicated by a single protein band upon analysis by SDS-PAGE. The protein band may be visualized by silver staining, Coomassie blue staining, or (if the protein is radiolabeled) by autoradiography.

### Assays

The purified polypeptides of the invention (including proteins, polypeptides, fragments, variants, analogs, and other forms) may be tested for the ability to bind

radionuclide, chromophore, enzyme that catalyze a colorimetric or fluorometric reaction, or other detectable moiety. The following are examples of assays that may be used:

binding partner. The cells then are washed to remove unbound labeled polypeptide, and the presence of cell-bound label is determined by a suitable technique, chosen according to the nature of the label.

One example of a binding assay procedure is as follows. A recombinant expression vector containing binding partner cDNA is constructed using methods well known in the art. The binding partner comprises an N-terminal cytoplasmic domain, a transmembrane region, and a C-terminal extracellular domain. CV1-EBNA-1 cells in 10 cm<sup>2</sup> dishes are transfected with the recombinant expression vector. CV-1/EBNA-1 cells (ATCC CRL 10478) constitutively express EBV nuclear antigen-1 driven from the CMV immediate-early enhancer/promoter. CV1-EBNA-1 was derived from the African Green Monkey kidney cell line CV-1 (ATCC CCL 70), as described by McMahon et al., *EMBO J.*, 10:2821 (1991).

The transfected cells are cultured for 24 hours, and the cells in each dish then are split into a 24-well plate. After culturing an additional 48 hours, the transfected cells (about  $4 \times 10^4$  cells/well) are washed with BM-NFDM, which is binding medium (RPMI 1640 containing 25 mg/ml bovine serum albumin, 2 mg/ml sodium azide, 20 mM Hepes pH 7.2) to which 50 mg/ml nonfat dry milk has been added. The cells then are incubated for 1 hour at 37°C with various concentrations of, for example, a soluble polypeptide/Fc fusion protein made as set forth above. Cells then are washed and incubated with a constant saturating concentration of a <sup>125</sup>I-mouse anti-human IgG in binding medium, with gentle agitation for 1 hour at 37°C. After extensive washing, cells are released *via* trypsinization.

The mouse anti-human IgG employed above is directed against the Fc region of human IgG and can be obtained from Jackson ImmunoResearch Laboratories, Inc., West Grove, PA. The antibody is radioiodinated using the standard chloramine-T method. The antibody will bind to the Fc portion of any polypeptide/Fc protein that has bound to the cells. In all assays, non specific binding of <sup>125</sup>I antibody is assayed

Cell bound <sup>125</sup>I antibody is quantified on a Packard Autogamma counter.

Affinity calculations (Scatchard, *Ann. N.Y. Acad. Sci.* 51:660 (1949)) are made using

Another type of suitable binding assay is a competitive binding assay. To illustrate, biological activity of a variant may be determined by assaying for the variant's ability to compete with the native protein for binding to the binding partner.

Competitive binding assays can be performed by conventional methodology. Reagents that may be employed in competitive binding assays include radiolabeled SVPH and intact cells expressing the binding partner (endogenous or recombinant) on the cell surface. For example, a radiolabeled soluble SVPH fragment can be used to compete with a soluble SVPH variant for binding to cells expressing the binding partner on the surface. Instead of intact cells, one could substitute a soluble binding partner/Fc fusion protein bound to a solid phase through the interaction of Protein A or Protein G (on the solid phase) with the Fc moiety. Chromatography columns that contain Protein A and Protein G include those available from Pharmacia Biotech, Inc., Piscataway, NJ.

Another type of competitive binding assay utilizes radiolabeled soluble binding partner, such as a soluble binding partner/Fc fusion protein, and intact cells expressing SVPH. Qualitative results can be obtained by competitive autoradiographic plate binding assays, while (Scatchard plots Scatchard, *Ann. N.Y. Acad. Sci.* 51:660 (1949)) may be utilized to generate quantitative results.

#### USE OF SVPH NUCLEIC ACID OR OLIGONUCLEOTIDES

In addition to being used to express polypeptides as described above, the nucleic acids of the invention, including DNA, RNA, mRNA, and oligonucleotides thereof can be used:

- as probes to identify nucleic acid encoding proteins having protease activity;
- to identify human chromosome number 1 or 4;
- to map genes on human chromosome number 1 or 4;

-45-

- as single-stranded sense or antisense oligonucleotides, to inhibit expression of polypeptides encoded by the SVPH-1, SVPH-3, or SVPH-4 gene;
- to detect defective genes in an individual; and
- for gene therapy.

#### Probes

The nucleotides of the invention can be used as probes to identify nucleic acid encoding proteins having similar activity or structure. Such uses include the use of fragments. Such fragments may comprise any length of contiguous nucleotides. In one embodiment, the fragment comprises at least about 17 contiguous nucleotides of a DNA sequence. In other embodiments, a DNA fragment comprises at least 30, or at least 60, contiguous nucleotides of a DNA sequence.

Because homologs of SEQ ID NOs:1-3 and 7-11, from other mammalian species are contemplated herein, probes based on the human DNA sequence of SEQ ID NOs:1-3 and 7-11 may be used to screen cDNA libraries derived from other mammalian species, using conventional cross-species hybridization techniques.

Using knowledge of the genetic code in combination with the amino acid sequences set forth above, sets of degenerate oligonucleotides can be prepared. Such oligonucleotides are useful as primers, e.g., in polymerase chain reactions (PCR), whereby DNA fragments are isolated and amplified.

#### Chromosome Mapping

All or a portion of the nucleic acids of SEQ ID NOs:1-3 and 7-11, including oligonucleotides, can be used by those skilled in the art using well-known techniques to identify human chromosomes and the specific locus thereof, that contains the DNA of SVPH family members. For example, all or a portion of SEQ ID NO 3, SEQ ID

NO 9 can be used to identify human chromosome 4. Useful techniques include, but are not limited to, using the sequence or portion including oligonucleotides, to

resolution), in situ hybridization to chromosome spreads (moderate resolution), and Southern blot hybridization to hybrid cell lines containing individual human chromosomes (low resolution).

For example, chromosomes can be mapped by radiation hybrid mapping. First, PCR is performed using the Whitehead Institute/MIT Center for Genome Research Genebridge4 panel of 93 radiation hybrids ([http://www-genome.wi.mit.edu/ftp/distribution/human\\_STS\\_releases/july97/rhmap/genebridge4.html](http://www-genome.wi.mit.edu/ftp/distribution/human_STS_releases/july97/rhmap/genebridge4.html)). Primers are used which lie within a putative exon of the gene of interest and which amplify a product from human genomic DNA, but do not amplify hamster genomic DNA. The results of the PCRs are converted into a data vector that is submitted to the Whitehead/MIT Radiation Mapping site on the internet (<http://www-seq.wi.mit.edu>). The data is scored and the chromosomal assignment and placement relative to known Sequence Tag Site (STS) markers on the radiation hybrid map is provided. The following web site provides additional information about radiation hybrid mapping: [http://www-genome.wi.mit.edu/ftp/distribution/human\\_STS\\_releases/july97/07-97.INTRO.html](http://www-genome.wi.mit.edu/ftp/distribution/human_STS_releases/july97/07-97.INTRO.html)).

#### Identifying Associated Diseases

As set forth below, sequences encoding SVPH-4a and SVPH-4b have been mapped by radiation hybrid mapping to the 1p11-13 region of chromosome 1. That region is associated with specific diseases which include but are not limited to fetal hydantoin syndrome, diphenylhydantoin toxicity, and pheochromocytoma. Thus, the nucleic acid of SEQ ID Nos:3, 10 and 11, or a fragment thereof, can be used by one skilled in the art using well-known techniques to analyze abnormalities associated with SVPH-4 genes. In addition, sequences encoding SVPH-1a, SVPH-1b, and SVPH-1c have been mapped by radiation hybrid mapping to the 4q34 region of chromosome 4. Thus, the nucleic acid of SEQ ID Nos:1, 7, 8, and 9, or a fragment

nucleic acid of SEQ ID No. 2, or a fragment thereof, to analyze abnormalities

associated with SVPH-3 gene. This enables one to distinguish conditions in which

this marker is rearranged or deleted. In addition, nucleic acid of SEQ ID NOs:1-3 and 7-11 or a fragment thereof can be used as a positional marker to map other genes of unknown location.

The DNA may be used in developing treatments for any disorder mediated (directly or indirectly) by defective, or insufficient amounts of, the genes corresponding to the nucleic acids of the invention. Disclosure herein of native nucleotide sequences permits the detection of defective genes, and the replacement thereof with normal genes. Defective genes may be detected in *in vitro* diagnostic assays, and by comparison of a native nucleotide sequence disclosed herein with that of a gene derived from a person suspected of harboring a defect in this gene.

#### Sense-Antisense

Other useful fragments of the nucleic acids include antisense or sense oligonucleotides comprising a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment of SEQ ID NOs:1-3 or 7-11. Such a fragment generally comprises at least about 14 nucleotides, preferably from about 14 to about 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, for example, Stein and Cohen, *Cancer Res.*, 48:2659 (1988) and van der Krol et al., *BioTechniques*, 6:958 (1988).

Binding of antisense or sense oligonucleotides to target nucleic acid sequences results in the formation of duplexes that block or inhibit protein expression by one of several means, including enhanced degradation of the mRNA by RNaseH, inhibition of splicing, premature termination of transcription or translation, or by other means. The antisense oligonucleotides thus may be used to block expression of proteins.

Antisense or sense oligonucleotides further comprise oligonucleotides having

endogenous nucleases. Such oligonucleotides, with resistant target linkages, are stable in the presence of nucleases (resistant to nuclease degradation) but retain sequence

Other examples of sense or antisense oligonucleotides include those oligonucleotides which are covalently linked to organic moieties, such as those described in WO 90/10448, and other moieties that increases affinity of the oligonucleotide for a target nucleic acid sequence, such as poly (L-lysine). Further still, intercalating agents, such as ellipticine, and alkylating agents or metal complexes may be attached to sense or antisense oligonucleotides to modify binding specificities of the antisense or sense oligonucleotide for the target nucleotide sequence.

Antisense or sense oligonucleotides may be introduced into a cell containing the target nucleic acid sequence by any gene transfer method, including, for example, lipofection,  $\text{CaPO}_4$ -mediated DNA transfection, electroporation, or by using gene transfer vectors such as Epstein-Barr virus.

Sense or antisense oligonucleotides also may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell.

Alternatively, a sense or an antisense oligonucleotide may be introduced into a cell containing the target nucleic acid sequence by formation of an oligonucleotide-lipid complex, as described in WO 90/10448. The sense or antisense oligonucleotide-lipid complex is preferably dissociated within the cell by an endogenous lipase.

#### USE OF SVPH POLYPEPTIDES AND FRAGMENTED POLYPEPTIDES

Uses include, but are not limited to, the following:

- Purifying proteins and measuring activity thereof

Other uses include, but are not limited to, the following:

- Controls for peptide fragmentation



- Identification of unknown proteins
- Preparation of Antibodies

#### Purification Reagents

Each of the polypeptides of the invention finds use as a protein purification reagent. For example, the polypeptides may be used to purify binding partner proteins. In particular embodiments, a polypeptide (in any form described herein that is capable of binding the binding partner) is attached to a solid support by conventional procedures. As one example, affinity chromatography columns containing functional groups that will react with functional groups on amino acid side chains of proteins are available (Pharmacia Biotech, Inc., Piscataway, NJ). In an alternative, a polypeptide/Fc protein (as discussed above) is attached to Protein A- or Protein G-containing chromatography columns through interaction with the Fc moiety.

The polypeptide also finds use in purifying or identifying cells that express the binding partner on the cell surface. Polypeptides are bound to a solid phase such as a column chromatography matrix or a similar suitable substrate. For example, magnetic microspheres can be coated with the polypeptides and held in an incubation vessel through a magnetic field. Suspensions of cell mixtures containing the binding partner expressing cells are contacted with the solid phase having the polypeptides thereon. Cells expressing the binding partner on the cell surface bind to the fixed polypeptides, and unbound cells then are washed away.

Alternatively, the polypeptides can be conjugated to a detectable moiety, then incubated with cells to be tested for binding partner expression. After incubation, unbound labeled matter is removed and the presence or absence of the detectable moiety on the cells is determined.

In a further alternative, mixtures of cells suspected of containing cells

binding. The resulting mixture then is passed through a column packed with avidin coated beads, whereby the high affinity of biotin for avidin provides binding of the

Berenson, et al., *J. Cell. Biochem.*, 10D:239 (1986). Washing to remove unbound material, and the release of the bound cells, are performed using conventional methods.

#### Measuring Activity

Polypeptides also find use in measuring the biological activity of the binding partner protein in terms of their binding affinity. The polypeptides thus may be employed by those conducting "quality assurance" studies, e.g., to monitor shelf life and stability of protein under different conditions. For example, the polypeptides may be employed in a binding affinity study to measure the biological activity of a binding partner protein that has been stored at different temperatures, or produced in different cell types. The proteins also may be used to determine whether biological activity is retained after modification of a binding partner protein (e.g., chemical modification, truncation, mutation, etc.). The binding affinity of the modified binding partner protein is compared to that of an unmodified binding partner protein to detect any adverse impact of the modifications on biological activity of the binding partner. The biological activity of a binding partner protein thus can be ascertained before it is used in a research study, for example.

#### Delivery Agents

The polypeptides also find use as carriers for delivering agents attached thereto to cells bearing the binding partner (or to other cell types found to express the binding partner on the cell surface) in *in vitro* or *in vivo* procedures.

Detectable (diagnostic) and therapeutic agents that may be attached to a polypeptide include, but are not limited to, toxins, other cytotoxic agents, drugs, radionuclides, chromophores, enzymes that catalyze a colorimetric or fluorometric reaction, and the like, with the particular agent being chosen according to the intended

use. For example, a toxin such as diphtheria toxin, *Pseudomonas*

radionuclides suitable for diagnostic use include, but are not limited to,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,

$^{99m}\text{Tc}$ ,  $^{111}\text{In}$ , and  $^{76}\text{Br}$ . Examples of radionuclides suitable for therapeutic use are  $^{131}\text{I}$ ,  $^{212}\text{At}$ ,  $^{75}\text{Br}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{212}\text{Pb}$ ,  $^{212}\text{Bi}$ ,  $^{109}\text{Pd}$ ,  $^{64}\text{Cu}$ , and  $^{67}\text{Cu}$ .

Such agents may be attached to the polypeptide by any suitable conventional procedure. The polypeptide comprises functional groups on amino acid side chains that can be reacted with functional groups on a desired agent to form covalent bonds, for example. Alternatively, the protein or agent may be derivatized to generate or attach a desired reactive functional group. The derivatization may involve attachment of one of the bifunctional coupling reagents available for attaching various molecules to proteins (Pierce Chemical Company, Rockford, Illinois). A number of techniques for radiolabeling proteins are known. Radionuclide metals may be attached to polypeptides by using a suitable bifunctional chelating agent, for example.

Conjugates comprising polypeptides and a suitable diagnostic or therapeutic agent (preferably covalently linked) are thus prepared. The conjugates are administered or otherwise employed in an amount appropriate for the particular application.

#### Therapeutic Agents

Polypeptides of the invention may be used in developing treatments for any disorder mediated (directly or indirectly) by defective, or insufficient amounts of the polypeptides. These polypeptides may be administered to a mammal afflicted with such a disorder.

The polypeptides may also be employed in inhibiting a biological activity of the binding partner, in *in vitro* or *in vivo* procedures. For example, a purified polypeptide may be used to inhibit binding of the binding partner to an endogenous cell surface binding partner. Biological effects that result from the binding of SVPH to endogenous binding partner thus are inhibited.

In addition, an SVPH binding partner may be administered to a mammal to partner.

Compositions of the present invention may contain a polypeptide polypeptide

biologically active fragments. In particular embodiments, the composition comprises a soluble polypeptide or an oligomer comprising soluble SVPH polypeptides or SVPH binding partner polypeptides.

Compositions comprising an effective amount of a polypeptide of the present invention, in combination with other components such as a physiologically acceptable diluent, carrier, or excipient, are provided herein. The polypeptides can be formulated according to known methods used to prepare pharmaceutically useful compositions. They can be combined in admixture, either as the sole active material or with other known active materials suitable for a given indication, with pharmaceutically acceptable diluents (e.g., saline, Tris-HCl, acetate, and phosphate buffered solutions), preservatives (e.g., thimerosal, benzyl alcohol, parabens), emulsifiers, solubilizers, adjuvants and/or carriers. Suitable formulations for pharmaceutical compositions include those described in *Remington's Pharmaceutical Sciences*, 16th ed. 1980, Mack Publishing Company, Easton, PA.

In addition, such compositions can be complexed with polyethylene glycol (PEG), metal ions, or incorporated into polymeric compounds such as polyacetic acid, polyglycolic acid, hydrogels, dextran, etc., or incorporated into liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts or spheroblasts. Such compositions will influence the physical state, solubility, stability, rate of *in vivo* release, and rate of *in vivo* clearance, and are thus chosen according to the intended application.

The compositions of the invention can be administered in any suitable manner, e.g., topically, parenterally, or by inhalation. The term "parenteral" includes injection, e.g., by subcutaneous, intravenous, or intramuscular routes, also including localized administration, e.g., at a site of disease or injury. Sustained release from implants is also contemplated. One skilled in the pertinent art will recognize that suitable dosages will vary, depending upon such factors as the nature of the disorder to be treated, the patient's body weight, age, and general condition, and the route of administration.

Compositions comprising nucleic acids in physiologically acceptable formulations are also contemplated. DNA may be formulated for injection, for example.

#### Research Agents

Another use of the polypeptide of the present invention is as a research tool for studying the biological effects that result from inhibiting binding partner/SVPH interactions on different cell types. Polypeptides also may be employed in *in vitro* assays for detecting the binding partner or SVPH or the interactions thereof.

#### Molecular Weight, Isoelectric Point Markers

The polypeptides of the present invention can be subjected to fragmentation into smaller peptides by chemical and enzymatic means, and the peptide fragments so produced can be used in the analysis of other proteins or polypeptides. For example, such peptide fragments can be used as peptide molecular weight markers, peptide isoelectric point markers, or in the analysis of the degree of peptide fragmentation. Thus, the invention also includes these polypeptides and peptide fragments, as well as kits to aid in the determination of the apparent molecular weight and isoelectric point of an unknown protein and kits to assess the degree of fragmentation of an unknown protein.

Although all methods of fragmentation are encompassed by the invention, chemical fragmentation is a preferred embodiment, and includes the use of cyanogen bromide to cleave under neutral or acidic conditions such that specific cleavage occurs at methionine residues (E. Gross, *Methods in Enz.*, 11:238-255 (1967)). This can further include additional steps, such as a carboxymethylation step to convert cysteine residues to an unreactive species. Table 1 summarizes the fragmentation pattern of SEQ ID NOs 12-16 following chemical cleavage with cyanogen bromide.

*Acetomobacter* protease I, Trypan, *Staphylococcus aureus* V<sub>8</sub> protease,

Endoprotease Asp N<sub>1</sub> or Endoprotease Lys C under conventional conditions to

cleave specifically on the carboxyl side of the asparagine residues present within the polypeptides of the invention. Arginylendo-peptidase can cleave specifically on the carboxyl side of the arginine residues present within these polypeptides. *Achromobacter* protease I can cleave specifically on the carboxyl side of the lysine residues present within the polypeptides (Sakiyama and Nakat, U.S. Patent No. 5,248,599; T. Masaki et al., *Biochim. Biophys. Acta*, 660:44-50 (1981); T. Masaki et al., *Biochim. Biophys. Acta*, 660:51-55 (1981)). Trypsin can cleave specifically on the carboxyl side of the arginine and lysine residues present within polypeptides of the invention. Enzymatic fragmentation may also occur with a protease that cleaves at multiple amino acid residues. For example, *Staphylococcus aureus* V8 protease can cleave specifically on the carboxyl side of the aspartic and glutamic acid residues present within polypeptides (D. W. Cleveland, *J. Biol. Chem.*, 3:1102-1106 (1977)). Endoproteinase Asp-N can cleave specifically on the amino side of the asparagine residues present within polypeptides. Endoproteinase Lys-C can cleave specifically on the carboxyl side of the lysine residues present within polypeptides of the invention. Other enzymatic and chemical treatments can likewise be used to specifically fragment these polypeptides into a unique set of specific peptides.

Of course, the peptides and fragments of the polypeptides of the invention can also be produced by conventional recombinant processes and synthetic processes well known in the art. With regard to recombinant processes, the polypeptides and peptide fragments encompassed by invention can have variable molecular weights, depending upon the host cell in which they are expressed. Glycosylation of polypeptides and peptide fragments of the invention in various cell types can result in variations of the molecular weight of these pieces, depending upon the extent of modification. The size of these pieces can be most heterogeneous with fragments of polypeptide derived from the extracellular portion of the polypeptide. Consistent polypeptides and peptide fragments can be obtained by using polypeptides derived entirely from the intracellular portion of the polypeptide.

Additional peptide sequences to both the amino and carboxyl terminal ends of

the polypeptides of the invention can be added. For example, a signal sequence can be added to the amino

and carboxyl terminal ends of polypeptides of the invention can be used to enhance expression of these polypeptides or aid in the purification of the protein. In addition, fusions of additional peptide sequences at the amino and carboxyl terminal ends of polypeptides of the invention will alter some, but usually not all, of the fragmented peptides of the polypeptides generated by enzymatic or chemical treatment. Of course, mutations can be introduced into polypeptides of the invention using routine and known techniques of molecular biology. For example, a mutation can be designed so as to eliminate a site of proteolytic cleavage by a specific enzyme or a site of cleavage by a specific chemically induced fragmentation procedure. The elimination of the site will alter the peptide fingerprint of polypeptides of the invention upon fragmentation with the specific enzyme or chemical procedure.

When the invention relates to the use of fragmented peptide molecular weight markers, those markers are preferably at least 10 amino acids in size. More preferably, these fragmented peptide molecular weight markers are between 10 and 100 amino acids in size. Even more preferable are fragmented peptide molecular weight markers between 10 and 50 amino acids in size and especially between 10 and 35 amino acids in size. Most preferable are fragmented peptide molecular weight markers between 10 and 20 amino acids in size.

Because the unique amino acid sequence of each fragment specifies a molecular weight, these fragments can thereafter serve as molecular weight markers using such analysis techniques to assist in the determination of the molecular weight of an unknown protein, polypeptides or fragments thereof. The molecular weight markers of the invention serve particularly well as molecular weight markers for the estimation of the apparent molecular weight of proteins that have similar apparent molecular weights and, consequently, allow increased accuracy in the determination of apparent molecular weight of proteins.

Among the methods for determining molecular weight are sedimentation, gel

*Nature*, 227:680-685 (1970). Conventionally, the method uses two separate lanes of a gel containing sodium dodecyl sulfate and a concentration of acrylamide between 6

conditions allows for increased accuracy. It is understood, of course, that many different techniques can be used for the determination of the molecular weight of an unknown protein using polypeptides of the invention, and that this embodiment in no way limits the scope of the invention.

In addition, each unglycosylated polypeptide or fragment thereof has a pI that is intrinsically determined by its unique amino acid sequence (which pI can be estimated by the skilled artisan using any of the computer programs designed to predict pI values currently available, calculated using any well-known amino acid pKa table, or measured empirically). Therefore these polypeptides and fragments thereof can serve as specific markers to assist in the determination of the isoelectric point of an unknown protein, polypeptide, or fragmented peptide using techniques such as isoelectric focusing. These polypeptide or fragmented peptide markers serve particularly well for the estimation of apparent isoelectric points of unknown proteins that have apparent isoelectric points close to that of the polypeptide or fragmented peptide markers of the invention.

The technique of isoelectric focusing can be further combined with other techniques such as gel electrophoresis to simultaneously separate a protein on the basis of molecular weight and charge. The ability to simultaneously resolve these polypeptide or fragmented peptide markers and the unknown protein under identical conditions allows for increased accuracy in the determination of the apparent isoelectric point of the unknown protein. This is of particular interest in techniques, such as two dimensional electrophoresis (T.D. Brock and M.T. Madigan, *Biology of Microorganisms* 76-77, Prentice Hall, 6th ed. (1991)), where the nature of the procedure dictates that any markers should be resolved simultaneously with the unknown protein. In addition, with such methods, these polypeptides and fragmented peptides thereof can assist in the determination of both the isoelectric point and molecular weight of an unknown protein or fragmented peptide.

It is also understood that the polypeptides and fragments thereof of the invention

can be used in conjunction with other techniques for the determination of molecular weight markers of the invention can be visualized using antibodies

specific for the polypeptides and fragments thereof of the invention.



detection is performed under conventional conditions that do not result in the detection of the unknown protein. It is understood that it may not be possible to generate antibodies against all polypeptide fragments of the invention, since small peptides may not contain immunogenic epitopes. It is further understood that not all antibodies will work in this assay; however, those antibodies which are able to bind polypeptides and fragments of the invention can be readily determined using conventional techniques.

The unknown protein is also visualized by using a conventional staining procedure. The molar excess of unknown protein to polypeptide or fragmented peptide molecular weight markers of the invention is such that the conventional staining procedure predominantly detects the unknown protein. The level of these polypeptide or fragmented peptide molecular weight markers is such as to allow little or no detection of these markers by the conventional staining method. The preferred molar excess of unknown protein to polypeptide molecular weight markers of the invention is between 2 and 100,000 fold. More preferably, the preferred molar excess of unknown protein to these polypeptide molecular weight markers is between 10 and 10,000 fold and especially between 100 and 1,000 fold.

It is understood of course that many techniques can be used for the determination and detection of molecular weight and isoelectric point of an unknown protein, polypeptides, and fragmented peptides thereof using these polypeptide molecular weight markers and peptide fragments thereof and that these embodiments in no way limit the scope of the invention.

In another embodiment, the analysis of the progressive fragmentation of the polypeptides of the invention into specific peptides (D. W. Cleveland et al., *J. Biol. Chem.* 252:1102-1106 (1977)), such as by altering the time or temperature of the fragmentation reaction, can be used as a control for the extent of cleavage of an unknown protein. For example, cleavage of the unknown protein with a known amount of a polypeptide can result in complete fragmentation of the unknown protein.

polypeptide can also result in complete fragmentation of the unknown protein.

As an example, cleavage of the polypeptide with a known amount of a known

ID NOs:4-6 and 12-16 with cyanogen bromide in the absence of glycosylation generates a unique set of fragmented peptide molecular weight markers with molecular weights as set forth in Table 1 on the following page.

Table 1. Molecular Weights of Peptide Fragments Generated by Cyanogen Bromide Digest

SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:6	SEQ ID NO:12	SEQ ID NO:13	SEQ ID NO:14	SEQ ID NO:15	SEQ ID NO:16
149.2	149.2	374.3	149.2	149.2	149.2	149.2	149.2
4,067.5	1,461.7	701.8	277.4	277.4	277.4	374.5	374.5
	3,960.4	1,154.0	596.7	596.7	596.7	701.8	701.8
	8,420.6	1,196.0	994.1	994.1	970.1	1,154.3	1,154.3
		1,724.0	1,106.2	1,201.3	994.1	1,174.3	1,174.3
		2,040.0	1,201.3	1,212.4	1,106.2	1,196.3	1,196.3
		3,614.0	1,212.4	1,465.8	1,201.3	1,757.0	1,757.0
		4,180.0	1,465.8	1,830.0	1,212.4	2,040.3	2,056.3
		5,327.0	1,830.0	1,908.1	1,465.8	2,330.9	2,330.9
		7,446.0	1,908.1	1,932.1	1,830.0	3,614.5	3,614.5
		7,603.0	2,006.3	2,218.6	1,908.1	4,179.8	4,179.8
		7,611.0	2,218.6	2,673.0	1,946.2	5,327.1	5,327.1
		15,692.0	2,673.0	3,657.1	1,960.2	6,065.8	6,065.8
			4,738.5	4,738.5	2,218.6	6,380.3	6,380.3
			12,088.8	12,088.8	2,673.0	7,446.3	6,487.2
			12,649.5	12,649.5	2,982.3	7,610.5	7,610.5
			16,801.8	16,801.8	4,738.5	10,741.4	10,741.4
			23,353.2	23,353.2	12,088.8	11,292.9	11,302.9
					12,649.5	15,692.4	15,692.4
					16,801.8		

in each peptide and the unique amino acid composition of each peptide determines its molecular weight. The molecular weight of each peptide fragment is determined by

determining molecular weight over the range of the molecular weights of the fragment.

In addition, the preferred purified polypeptides of the invention (SEQ ID NOs:4-6 and 12-16) have calculated molecular weights of approximately 4,199; 13,938; 55,209; 86,983; 89,459; 92,781; 88,923; and 87,990 Daltons, respectively. Thus, where an intact protein is used, the use of these polypeptide molecular weight markers allows increased accuracy in the determination of apparent molecular weight of proteins that have apparent molecular weights close to these weights.

Finally, as to the kits that are encompassed by the invention, the constituents of such kits can be varied, but typically contain the polypeptide and fragmented peptide molecular weight markers. Also, such kits can contain the polypeptides wherein a site necessary for fragmentation has been removed. Furthermore, the kits can contain reagents for the specific cleavage of the polypeptide and the unknown protein by chemical or enzymatic cleavage. Kits can further contain antibodies directed against polypeptides or fragments thereof of the invention.

#### Identification of Unknown Proteins

As set forth above, a polypeptide or peptide fingerprint can be entered into or compared to a database of known proteins to assist in the identification of the unknown protein using mass spectrometry (W.J. Henzel et al., *Proc. Natl. Acad. Sci. USA*, 90:5011-5015 (1993); D. Fenyo et al., *Electrophoresis*, 19:998-1005 (1998)). A variety of computer software programs to facilitate these comparisons are accessible via the Internet, such as Protein Prospector (Internet site: [prospector.uscf.edu](http://prospector.uscf.edu)), MultiIdent (Internet site: [www.expasy.ch/sprot/multiident.html](http://www.expasy.ch/sprot/multiident.html)), PeptideSearch (Internet site: [www.mann.embl-heidelberg.de/deSearch/FR\\_PeptideSearch\\_Form.html](http://www.mann.embl-heidelberg.de/deSearch/FR_PeptideSearch_Form.html)), and ProFound (Internet site: [www.chait-spi.rockefeller.edu/cgi-bin/](http://www.chait-spi.rockefeller.edu/cgi-bin/)

[www.chait-spi.rockefeller.edu/cgi-bin/](http://www.chait-spi.rockefeller.edu/cgi-bin/)).

The present invention also includes the use of molecular weight markers and molecular weights derived from sequence databases to assist in determining the identity of the

In addition, a polypeptide or peptide digest can be sequenced using tandem mass spectrometry (MS/MS) and the resulting sequence searched against databases (J.K. Eng, et al., *J. Am. Soc. Mass Spec.*, 5:976-989 (1994); M. Mann and M. Wilm, *Anal. Chem.*, 66:4390-4399 (1994); J.A. Taylor and R.S. Johnson, *Rapid Comm. Mass Spec.*, 11:1067-1075 (1997)). Searching programs that can be used in this process exist on the Internet, such as Lutefisk 97 (Internet site: [www.lsbcc.com:70/Lutefisk97.html](http://www.lsbcc.com:70/Lutefisk97.html)), and the Protein Prospector, Peptide Search and ProFound programs described above.

Therefore, adding the sequence of a gene and its predicted protein sequence and peptide fragments to a sequence database can aid in the identification of unknown proteins using mass spectrometry.

### Antibodies

Antibodies that are immunoreactive with the polypeptides of the invention are provided herein. Such antibodies specifically bind to the polypeptides via the antigen-binding sites of the antibody (as opposed to non-specific binding). Thus, the polypeptides, fragments, variants, fusion proteins, etc., as set forth above may be employed as "immunogens" in producing antibodies immunoreactive therewith. More specifically, the polypeptides, fragment, variants, fusion proteins, etc. contain antigenic determinants or epitopes that elicit the formation of antibodies.

These antigenic determinants or epitopes can be either linear or conformational (discontinuous). Linear epitopes are composed of a single section of amino acids of the polypeptide, while conformational or discontinuous epitopes are composed of amino acids sections from different regions of the polypeptide chain that are brought into close proximity upon protein folding (C. A. Janeway, Jr. and P. Travers, *Immuno Biology* 3:9, Garland Publishing Inc., 2nd ed. (1996)). Because folded proteins have complex surfaces, the number of epitopes available is quite large. It is well known that the conformation of the protein is important for the

Garland Publishing Inc., 2nd ed. (1996)). Epitopes may be identified by any of the methods known in the art.

Thus, one aspect of the present invention relates to the antigenic epitopes of the polypeptides of the invention. Such epitopes are useful for raising antibodies, in particular monoclonal antibodies, as described in more detail below. Additionally, epitopes from the polypeptides of the invention can be used as research reagents, in assays, and to purify specific binding antibodies from substances such as polyclonal sera or supernatants from cultured hybridomas. Such epitopes or variants thereof can be produced using techniques well known in the art such as solid-phase synthesis, chemical or enzymatic cleavage of a polypeptide, or using recombinant DNA technology.

As to the antibodies that can be elicited by the epitopes of the polypeptides of the invention, whether the epitopes have been isolated or remain part of the polypeptides, both polyclonal and monoclonal antibodies may be prepared by conventional techniques. See, for example, *Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Kennet et al. (eds.), Plenum Press, New York (1980); and *Antibodies: A Laboratory Manual*, Harlow and Land (eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1988).

Hybridoma cell lines that produce monoclonal antibodies specific for the polypeptides of the invention are also contemplated herein. Such hybridomas may be produced and identified by conventional techniques. One method for producing such a hybridoma cell line comprises immunizing an animal with a polypeptide; harvesting spleen cells from the immunized animal; fusing said spleen cells to a myeloma cell line, thereby generating hybridoma cells; and identifying a hybridoma cell line that produces a monoclonal antibody that binds the polypeptide. The monoclonal antibodies may be recovered by conventional techniques.

The monoclonal antibodies of the present invention include chimeric antibodies, e.g., humanized versions of murine monoclonal antibodies. Such humanized antibodies may be prepared by known techniques and offer the advantage

of having a murine antibody (or just the antigen binding site thereof) and a constant region derived from a human antibody. Alternatively, a humanized antibody, formed from

region fragment (lacking the antigen-binding site) derived from a human antibody. Procedures for the production of chimeric and further engineered monoclonal antibodies include those described in Riechmann et al., *Nature*, 332:323 (1988); Liu et al., *PNAS*, 84:3439 (1987); Larrick et al., *Bio Technology*, 7:934 (1989), and Winter and Harris, *TIPS*, 14:139 (May 1993). Procedures to generate antibodies transgenically can be found in GB 2,272,440, US Patent Nos. 5,569,825 and 5,545,806 and related patents claiming priority therefrom, all of which are incorporated by reference herein.

Antigen-binding fragments of the antibodies, which may be produced by conventional techniques, are also encompassed by the present invention. Examples of such fragments include, but are not limited to, Fab and F(ab')<sub>2</sub> fragments. Antibody fragments and derivatives produced by genetic engineering techniques are also provided.

In one embodiment, the antibodies are specific for the polypeptides of the present invention and do not cross-react with other proteins. Screening procedures by which such antibodies may be identified are well known, and may involve immunoaffinity chromatography, for example.

#### Uses Thereof

The antibodies of the invention can be used in assays to detect the presence of the polypeptides or fragments of the invention, either *in vitro* or *in vivo*. The antibodies also may be employed in purifying polypeptides or fragments of the invention by immunoaffinity chromatography.

Those antibodies that additionally can block binding of the polypeptides of the invention to the binding partner may be used to inhibit a biological activity that results from such binding. Such blocking antibodies may be identified using any suitable assay procedure, such as by testing antibodies for the ability to inhibit binding of SYPH to a binding partner. The binding partner may be a protein, a cell, or a cell component.

ability to inhibit SYPH-mediated cell lysis, for example.

Such an antibody may be employed in an *in vitro* procedure, or administered *in vivo* to inhibit a biological activity mediated by the entity that generated the antibody. Disorders caused or exacerbated (directly or indirectly) by the interaction of SVPH with cell surface binding partner thus may be treated. A therapeutic method involves *in vivo* administration of a blocking antibody to a mammal in an amount effective in inhibiting an SVPH-binding partner-mediated biological activity. Monoclonal antibodies are generally preferred for use in such therapeutic methods. In one embodiment, an antigen-binding antibody fragment is employed.

Antibodies may be screened for agonistic (*i.e.*, ligand-mimicking) properties. Such antibodies, upon binding to cell surface binding partner, induce biological effects (e.g., transduction of biological signals) similar to the biological effects induced when SVPH binds to cell surface binding partner.

Compositions comprising an antibody that is directed against SVPH or SVPH binding partner, and a physiologically acceptable diluent, excipient, or carrier, are provided herein. Suitable components of such compositions are as described above for compositions containing SVPH or SVPH binding partner proteins.

Also provided herein are conjugates comprising a detectable (e.g., diagnostic) or therapeutic agent, attached to the antibody.

The following examples are provided to further illustrate particular embodiments of the invention, and are not to be construed as limiting the scope of the present invention.

#### **EXAMPLE 1: Isolation of SVPH Nucleic Acids**

A search of the GenBank DNA sequence database revealed two ESTs that share homology with ADAM20 and ADAM21. X85598 showed similarity to the Cys-rich region of ADAM20, while A1214466 showed similarity to the same region in ADAM21. Both ESTs were derived from testis mRNA

to the library (Clontech cat no. HT 5924a), (Crenetti et al., *Proc. Natl. Acad. Sci. USA*, 83:3223-3227 (1986)), at 42° C and washing at 42° C in 2x SSC 0.1% SDS solution 32x

labeled deoxyoligonucleotides (5'-CACCTAAGGTGTTCAATTC'TTTG-3' (SEQ ID NO:17), 5'-CAAATACTGCAAGTGAGACTTGC-3' (SEQ ID NO:18), 5'-TGCACAAC'TACGTGTGGTGTACCC-3' (SEQ ID NO:19), and 5'-GAGCC'ACTGCAATTGAAAAAGTGCC-3' (SEQ ID NO:20). SVPH-4 clones were isolated under the same conditions using <sup>32</sup>P-labeled deoxyoligonucleotides (AATGATGCTCTTGCATGGTCG (SEQ ID NO:21), CTTTCACGGAGCCCATGTAGTTGCAG (SEQ ID NO:22), and TGAAGGAGAAAAACGCGCAGATGTCGG (SEQ ID NO:23). DNAs from positively hybridizing phages were purified and characterized by restriction endonuclease mapping, Southern blot analysis, and DNA sequencing.

### **EXAMPLE 2: DNA Sequence Analysis of SVPH**

SVPH-1c has an open reading frame of 820 amino acids (GenBank accession number AF171929) that encodes all of the ADAMs domains, including a signal sequence, pro-domain with a Cys switch, catalytic domain with a zinc-binding motif and a Met-turn, disintegrin domain, cysteine-rich domain, a transmembrane domain, and a cytoplasmic domain. However, SVPH-1c (as well as SVPH-1a and SVPH-1b) has a His residue (His 333) instead of a Glu residue in the zinc-binding motif that may affect catalytic activity. The Glu residue binds a water molecule via hydrogen binding and is required for enzymatic activity (Stocker, W. et al., *Protein Sci.*, 4:823-840 (1995)). SVPH-1a and SVPH-1b represent alternative forms of SVPH-1c with differences in the cytoplasmic domain. SVPH-1a has a deletion of 54 amino acids resulting in a protein of 766 amino acids (GenBank accession number AF171930), while SVPH-1b has a divergent 38 amino acid C-terminus resulting in a protein with 787 amino acids (GenBank accession number AF171931). These three forms of SVPH-1 encode cytoplasmic domains of 121, 67, and 88 amino acids, respectively. An unusual feature of the cytoplasmic domain of SVPH-1c is the sequence

.....

.....  
 number AF171932) with all of the domains found in ADAMs. Unlike the SVPH-1



catalytic domain. One cDNA, presumably from an alternative RNA splicing event, deletes nine amino acids in the cytoplasmic domain and has been designated SVPH-4b (GenBank accession number AF171933). Interestingly, SVPH-4a and SVPH-4b contain a repeat sequence, QEESK(T/A)KTG (SEQ ID NO:33), in the cytoplasmic domain, which was not found in GenBank.

As noted above, SVPH-1a, SVPH-1b, and SVPH-1c diverge from the consensus zinc-binding cluster (**HEXXHXXGXXHD**) (SEQ ID NO:31) in the catalytic domain with a Glu to His change at position 333. To analyze these proteins further, DNA and protein sequence multiple alignments of all known mammalian ADAMs (<http://www.mcd.virginia.edu/~jag6n/adams.html>) were produced using the PILEUP program from the Wisconsin Package (Wisconsin Package 10.1, Genetics Computer Group, Madison, WI). Protein multiple alignments were generated using the modified PAM scoring matrix of Gribskov and Burgess (Gribskov, M. et al., *Nucleic Acids Res.*, 14:6745-6763 (1986)) provided in the Wisconsin Package, with gap-open and gap-extend penalties of 30 and 1, respectively. Nucleic acid multiple alignments were generated using a scoring matrix with A, C, G, T matches scoring unity, mismatches scoring zero, and gap-open and gap-extend penalties of 5 and 1 respectively. Unrooted maximum parsimony trees were estimated by the Wisconsin Package implementation of PAUP (version 4.0), starting from multiple alignments produced by PILEUP. PAUP parameters were set to use accelerated transformation character-state optimization with unordered, equally weighted characters.

This alignment was used to infer a maximum parsimony phylogeny (Fig. 2). Due to the large number of taxa involved, the phylogeny was inferred using a heuristic tree search, which does not perform an exhaustive search of all possible tree topologies. Examination of the phylogenetic tree revealed an interesting pattern with respect to the presence of a zinc-binding motif. The ADAM sequences can be divided into two well-separated regions of the phylogeny, as marked by the arrow in Fig. 2.

#### Phylogenetic Analysis of ADAMs

Line 1. Closely related members that do not have a consensus zinc-binding motif (ADAMs 4, 6, 7, 11, 22, 23, and SVPH-1) presumably arose from a single ADAM

example, ADAM4, ADAM7, and SVPH-1 all possess the three His residues and the Asp after the third conserved His. Finally, the corresponding region in ADAMs 2, 3, 5, 18 and 27 is quite distinct. As these sequences form clusters quite divergent from the zinc-binding site-containing ADAMs, it is most likely that the zinc-binding site arose once in the common ancestor to the ADAMs and was lost in those lineages which do not possess a zinc-binding site (denoted by an 'X' in Fig. 2).

### **EXAMPLE 3: Chromosome Mapping of SVPH**

Radiation hybrid mapping (Walter, et al., *Nat. Genet.*, 7: 22-28 (1994)) was done using the GeneBridge 4 radiation-hybrid mapping panel (Research Genetics, Huntsville, AL). The panel was screened with specific primer pairs for SVPH-1 (sense: 5'-TCGATAATGCATGAAGGCAACCCACC-3' (SEQ ID NO:24) and antisense: 5'-CAAGTCTCACTTGCAGTATTTGCGCC-3' (SEQ ID NO:25), and SVPH-4 (sense; 5'-GCCACTGCATGTATGGGTG-3' (SEQ ID NO:26) and antisense: 5'-GACACTCTTTGCTTTGGGTG-3' (SEQ ID NO:27) which generated products of 298 and 263 bp, respectively. PCR products were subjected to Southern blot analysis using an internal oligonucleotide probe specific for each gene. Data from two independent PCR screenings for each primer pair were scored against STS markers from the Whitehead Institute/MIT Center for Genome Research database using the statistical program RHMAPPER. LOD scores were >3.0 in all cases.

SVPH-1a, SVPH-1b, and SVPH-1c were mapped to chromosome 4q34, 1.51 cR distal from AFM312WGL. The sequential order of known markers relative to SVPH-1 on the Whitehead framework map was D4S1545, PDGHI (Hydroxyprostaglandin Dehydrogenase 15)/SVPH-1/WI-21773/GPM6A (Glycoprotein M6A). This region is syntenic to mouse chromosome 8. SVPH-4a and SVPH-4b were mapped to chromosome 1p11-13, 1.65 cR distal to D1S453. The sequential order of markers relative to SVPH-4 on the Whitehead framework map was CD2

#### **EXAMPLE 4: Tissue Distribution of SVPH**

Northern blot analysis was used to determine the tissue distribution of SVPH-1 and SVPH-4. Northern blots were purchased from Clontech (catalog number 7760-1, 7759-1, 7755-1, 7750-1). Each lane contained approximately 2 µg of the indicated poly A<sup>+</sup> RNA. The blots were treated with Stark's buffer (50% formamide, 50mM KPO<sub>4</sub>, 5 x SSC, 1% SDS, 5X Denhardt's, 0.05% sarcosyl, 300mg/ml salmon sperm DNA) at 63°C for at least 1h and then probed with <sup>32</sup>P-labeled riboprobes in Stark's buffer at 63°C, overnight (Cosman et al., *Nature*, 312:768-771 (1984)). Blots were then sequentially washed to high stringency (0.1 x SSC, 0.1% SDS, 63°C) and exposed to film. Films were developed in an automated x-ray film processor. SVPH-1 (nt 1068 to 1786 of SEQ ID NOs:7-9) and SVPH-4 (nt 1343 to 1779 of SEQ ID NOs:10-11) anti-sense riboprobes were prepared by *in vitro* transcription from a T7 RNA promoter with a commercially available kit (MAXIscript, Ambion, Inc., Austin, TX) using [ $\alpha$ -<sup>32</sup>P]-UTP as the labeled nucleotide.

As indicated in Figure 1, both SVPH-1 and SVPH-4 were specifically expressed in testes with a single mRNA species of approximately 3.0 kb. No signals were detected in the other RNA samples.

#### **EXAMPLE 5: Monoclonal Antibodies**

This example illustrates a method for preparing monoclonal antibodies that bind an SVPH-1, SVPH-1a, SVPH-1b, SVPH-1c, SVPH-4, SVPH-4a or SVPH-4b polypeptide. Suitable immunogens that may be employed in generating such antibodies include, but are not limited to, purified SVPH-1, SVPH-1a, SVPH-1b, SVPH-1c, SVPH-4, SVPH-4a or SVPH-4b polypeptide or an immunogenic fragment thereof such as the extracellular domain, or fusion proteins containing SVPH-1, SVPH-1a, SVPH-1b, SVPH-1c, SVPH-4, SVPH-4a or SVPH-4b (e.g., a soluble SVPH-1/Fc fusion protein).

Using conventional techniques such as those described in U.S. Patent 4,411,993

Briefly, mice are immunized with SVPH-1, SVPH-1a, SVPH-1b, SVPH-1c, SVPH-4,

injected in amounts ranging from 10-100 µg subcutaneously or intraperitoneally. Ten to twelve days later, the immunized animals are boosted with additional immunogen emulsified in incomplete Freund's adjuvant. Mice are periodically boosted thereafter on a weekly to bi-weekly immunization schedule. Serum samples are periodically taken by retro-orbital bleeding or tail-tip excision to test for SVPH-1, SVPH-1a, SVPH-1b, SVPH-1c, SVPH-4, SVPH-4a or SVPH-4b antibodies by dot blot assay, ELISA (Enzyme-Linked Immunosorbent Assay) or inhibition of binding partner binding.

Following detection of an appropriate antibody titer, positive animals are provided one last intravenous injection of SVPH-1, SVPH-1a, SVPH-1b, SVPH-1c, SVPH-4, SVPH-4a or SVPH-4b in saline. Three to four days later, the animals are sacrificed, spleen cells harvested, and spleen cells are fused to a murine myeloma cell line, e.g., NS1 or preferably P3x63Ag8.653 (ATCC CRL 1580). Fusions generate hybridoma cells, which are plated in multiple microtiter plates in a HAT (hypoxanthine, aminopterin and thymidine) selective medium to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.

The hybridoma cells are screened by ELISA for reactivity against purified SVPH-1, SVPH-1a, SVPH-1b, SVPH-1c, SVPH-4, SVPH-4a or SVPH-4b by adaptations of the techniques disclosed in Engvall et al., *Immunochem.* 8:871, 1971 and in U.S. Patent 4,703,004. A preferred screening technique is the antibody capture technique described in Beckmann et al., *J. Immunol.* 144:4212, (1990). Positive hybridoma cells can be injected intraperitoneally into syngeneic BALB/c mice to produce ascites containing high concentrations of anti-SVPH-1, SVPH-1a, SVPH-1b, SVPH-1c, SVPH-4, SVPH-4a or SVPH-4b monoclonal antibodies. Alternatively, hybridoma cells can be grown *in vitro* in flasks or roller bottles by various techniques. Monoclonal antibodies produced in mouse ascites can be purified by ammonium sulfate precipitation, followed by gel exclusion chromatography. Alternatively, affinity chromatography based upon binding of antibody to Protein A or Protein G can

### **EXAMPLE 6: Binding Assay**

Full length SVPH-1, SVPH-1a, SVPH-1b, SVPH-1c, SVPH-4, SVPH-4a or SVPH-4b is expressed and tested for the ability to bind its binding partner. The binding assay is conducted as follows.

A fusion protein comprising a leucine zipper peptide fused to the N-terminus of a soluble binding partner polypeptide (LZ-binding partner) is employed in the assay. An expression construct is prepared, essentially as described for preparation of the FLAG®-binding partner expression construct in Wiley et al., *Immunity*, 3:673-682, (1995), which is hereby incorporated by reference, except that DNA encoding the FLAG® peptide is replaced with a sequence encoding a modified leucine zipper that allows for trimerization. The construct, in expression vector pDC409, encodes a leader sequence derived from human cytomegalovirus, followed by the leucine zipper moiety fused to the N-terminus of a soluble binding partner polypeptide. The LZ-binding partner is expressed in CHO cells, and can be purified from the culture supernatant.

The expression vector designated pDC409 is a mammalian expression vector derived from the pDC406 vector described in McMahan et al., *EMBO J.* 10:2821-2832, (1991), which is hereby incorporated by reference. Features added to pDC409 (compared to pDC406) include additional unique restriction sites in the multiple cloning site (mcs); three stop codons (one in each reading frame) positioned downstream of the mcs; and a T7 polymerase promoter, downstream of the mcs, that facilitates sequencing of DNA inserted into the mcs.

For expression of full length human SVPH-1, SVPH-1a, SVPH-1b, SVPH-1c, SVPH-4, SVPH-4a or SVPH-4b protein, the entire coding region (*i.e.*, the DNA sequence presented in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, or SEQ ID NO:11) is amplified by polymerase chain reaction (PCR). The isolated and amplified DNA is inserted into the expression

expressing recombinant SVPH-1, SVPH-1a, SVPH-1b, SVPH-1c, SVPH-4, SVPH-4a or SVPH-4b polypeptide, as discussed above. Cells are cultured in DMEM

48 hours after transfection, cells are detached non-enzymatically and incubated with LZ-binding partner (5 mg/ml), a biotinylated anti-LZ monoclonal antibody (5 mg/ml), and phycoerythrin-conjugated streptavidin (1:400), before analysis by fluorescence-activated cell scanning (FACS). The cytometric analysis is conducted on a FACScan (Beckton Dickinson, San Jose, CA).

The cells expressing LZ-binding partner will show significantly enhanced binding of SVPH-1, SVPH-1a, SVPH-1b, SVPH-1c, SVPH-4, SVPH-4a or SVPH-4b, compared to the control cells not expressing LZ-binding partner.

The specification is most thoroughly understood in light of the teachings of the references cited within the specification which are hereby incorporated by reference. The embodiments within the specification provide an illustration of embodiments of the invention and should not be construed to limit the scope of the invention. The skilled artisan readily recognizes that many other embodiments are encompassed by the invention.